

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.



Date : 24th August, 2021

To,
National Stock Exchange of India Limited
Mumbai

Scrip Code : ARVEE

Sub : Submission of Annual Report for the year ended on 31.3.2021

Most Respectfully,

With reference to the above subject and pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the Annual Report of the Company for the year ended on 31st March, 2021.


The said Annual Report is dispatched to the Shareholders of the Company.

The Annual Report is available on the website of the Company.

Kindly acknowledge the receipt of the same.

Thanking You,

For, Arvee Laboratories (India) Limited


Saurin Gandhi
Chief Financial Officer



ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road,
Ambli, Ahmedabad, Gujarat - 380058

compliance@arveelabs.com CIN: L24231GJ2012PLC068778

www.arveelabs.com, Tel: 91- 2717-430479

Directors

Shalin Sudhakarbhair Patel

Shalin Bharatbhair Chokshi

Mr. Vishal Nitin Mehta

Mr. Parag Manubhai Shah (w.e.f. 27/06/2020)

Mr. Dipen Ashit Dalal

Mrs. Neetu Rishi Jalan (w.e.f. 12/2/2021)

Mrs. Chandrakala Ashok Bhatt (upto 17/7/2021)

Managing Director

Whole Time Director

Independent Director

Independent Director

Independent Director

Independent Director

Independent Director

Company Secretary

Mrs. Raina Singh Chauhan

Chief Financial Officer

Mr. Saurin Ajit Gandhi

Bankers

Standard Chartered Bank

Secretarial Auditors

M/s. Jalan Alkesh & Associates,

Company Secretaries, Ahmedabad

Contents of Annual Report

Sr. No.	Particulars	Page Nos.
1	Notice of Annual General Meeting	1 to 28
2	Proxy form	29 to 31
3	Directors Report	32 to 43
4	Nomination and Remuneration Policy	44 to 47
5	Secretarial Audit Report	48 to 51
6	Annual Secretarial Compliance	52 to 53
7	Corporate Governance	54 to 72
8	Management Discussion and Analysis	73 to 79
9	Certificate on Compliance of Corporate Governance	80 to 81
10	Details under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014	82 to 84
11	Certificate of Non Disqualification of Directors	85 to 86
12	Route Map	87 to 87
13	Independent Auditors Report	88 to 95
14	Balance Sheet	96 to 97
15	Statement of Profit and Loss	98 to 99
16	Cash Flow Statement	100 to 100
17	Notes	101 to 128

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road,
Ambli, Ahmedabad, Gujarat - 380058

compliance@arveelabs.com CIN: L24231GJ2012PLC068778

www.arveelabs.com, Tel: 91- 2717-430479

=====

NOTICE

Notice is hereby given that the 10th Annual General Meeting of the members of Arvee Laboratories (India) Limited will be held at on Friday, 24th September, 2021 at 11:30 a.m. at the Registered Office of the Company situated at 403, Entice, Nr. Jayantilal Park BRTS, Iskcon-Bopal Road, Ambli, Ahmedabad, Gujarat - 380058 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the audited Balance Sheet as at 31st March, 2021 and Statement of Income and Expenditure and Cash Flow Statement for the year ended on 31st March, 2021 and the Reports of the Board of Directors and Auditors thereon and documents annexed thereto.
2. To reappoint Mr. Shalin Bharatbhai Chokshi (having Director Identification Number: 00191903) a Director of the Company who retires by rotation and being eligible offers himself for reappointment.

APPOINTMENT OF AUDITORS:

3. "RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 as amended from time to time or any other law for the time being in force (including any statutory modification or amendment thereto or reenactment thereof for the time being in force), as recommended by the Board of Directors of the company, M/s. Jaimin Deliwala & Co. Chartered Accountants (FRN.: 103861W), Ahmedabad be and are hereby appointed as Statutory Auditors of the Company to hold office from the conclusion of annual general meeting for the year ended on 31st March, 2021 for a period of five years to conduct statutory audit of the company commencing from the financial year 2021 - 2022 on such remuneration as may be determined and recommended by the Audit Committee in consultation with the Auditors and duly approved by the Board of Directors of the Company."

SPECIAL BUSINESS

4. Appointment of Statutory Auditors to fill Casual Vacancy

To appoint statutory auditor of the Company and to fix their remuneration and it thought fit to pass with or without modification the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 as amended from time to time or any other law for the time being in force (including any statutory modification or amendment thereto or reenactment thereof for the time being in force), as recommended by the Board of Directors of the company, M/s. Jaimin Deliwala & Co. (New Auditor) Chartered Accountants (FRN.: 103861W), Ahmedabad be and are hereby appointed as Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/s. KCJM & Associates, Chartered Accountants (FRN.: 0121324W), Ahmedabad.

RESOLVED FURTHER THAT M/s. Jaimin Deliwala & Co., Chartered Accountants, be and are hereby appointed as Statutory Auditors of the Company from this Annual General Meeting and that they shall hold the office of the Statutory Auditors of the Company from 18th July, 2021 till the conclusion of Annual General Meeting for the year 2021 as may be determined and recommended by the Audit Committee in consultation with the Auditors and duly approved by the Board of Directors of the Company.

5. To consider and if thought fit to pass with or without modification the following resolution as an Special Resolution for appointment of Mrs. Neetu Rishi Jalan as an Independent Director :

“RESOLVED THAT, pursuant to the provision of Section 149, 150 and 152 and other applicable provision, if any, of the Companies Act, 2013 and rules made there under read with Schedule IV of the Companies Act, Mrs. Neetu Rishi Jalan (DIN : 08719470) who was appointed as an Additional Director with effect from 12th February, 2021 under Section 161 of the Companies Act 2013 be and is hereby appointed as Independent Director of the Company to hold office for a term up to five consecutive years commencing from 12th February, 2021 and shall not be liable to retire by rotation”.

6. To consider and if thought fit to pass with or without modification the following resolution as an Special Resolution for grant of loans, or providing Security or Guarantee for the loans availed by other entities in which the Directors of the Company are interested.

“RESOLVED THAT pursuant to the provisions of Section 185 and other applicable provisions, if any, of the Companies Act, 2013 (the "Act") and the Companies (Meeting of Board and its Powers) Rules, 2014 (including any statutory modification(s), clarification(s), substitution(s) or re-enactment(s) thereof for the time being in force), consent of the Members of the Company, be and is hereby accorded to grant loans, Investment and/or giving of security and/or guarantee for the loans availed or to be availed by the

following body corporates one in which one or more Director(s) of the Company are interested, either directly or indirectly:

a. Arvee Speciality Chemicals Private Limited

“RESOLVED FURTHER THAT the maximum amount of Loans and/or guarantee and/or Security of an aggregate amount not exceeding Rs. 10 crores (Rupees Ten Crores only) at any time provided that such loans are utilized by the borrowing company for its principal business activities.”

“RESOLVED FURTHER THAT for the purpose of giving effect to the aforesaid resolution the Board of Directors of the Company be and is hereby authorized, to approve, decide, vary or modify the terms and conditions applicable for the aforesaid loan, Investment , Corporate Guarantee and to do all such acts, deeds, matters and things as they may, in their absolute discretion deem necessary, desirable or expedient and things in connection therewith and incidental thereto as the Board in its absolute discretion deem fit without being required to seek any further consent or approval of the members or otherwise to the end and intent that they shall be deemed to have given their approval thereto expressly by the authority of this resolution.”

“FURTHER RESOLVED THAT the Chairman and Managing Director of the Company or any one of the Directors of the Company or the Company Secretary of the Company be and are hereby authorised to do all such things, acts, deeds and matters as may be considered necessary, usual, proper or expedient to give effect to the above resolution.”

7. To consider and if thought fit to pass with or without modification the following resolution as an Special Resolution for remuneration for remaining tenure of Shalin Sudhakarbhair Patel Managing Director of the Company :

“RESOLVED THAT pursuant to the provisions of Sections 196, 197 and 198 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (hereinafter referred to as the “Act”) and the Rules framed thereunder, (including any statutory modifications or re-enactment thereof, for the time being in force) and the Articles of Association of the Company and subject to such other approvals as may be necessary, the approval of the Members be and hereby accorded for the payment of the remuneration of Rs. 5.00 Lacs per month to Mr. Shalin Sudhakarbhair Patel (DIN: 01779902), Chairman and Managing Director, for the remaining period namely , from October 1, 2020 to December 3, 2022”;

“RESOLVED FURTHER THAT the Ministry of Corporate Affairs (MCA) through its notification dated 12 September 2018 under notified provisions of the Companies (Amendment) Act, 2017 (Amendment Act, 2017) and amended schedule V of Companies Act, 2013. Respectively to the same, the Central Government amends Schedule V of Companies Act, 2013 vide Notification

dated 12th September, 2018 and amends Part I and Part II related to conditions to be fulfilled for the Appointments and Remuneration of a Managing or Whole-time director or a Manager without the approval of the Central Government but by the approval of members in the general meeting via special resolution.

“RESOLVED FURTHER THAT the Board of Directors and the Nomination & Remuneration Committee be and is hereby authorised to vary such terms of appointment & remuneration specified above from time to time to the extent the Board of Directors may deem appropriate, provided that such variation, as the case may be, as specified under the relevant provisions of the Companies Act, 2013 and/or Schedule V.

RESOLVED FURTHER THAT in the event in any financial year during the tenure of the Managing Director, the Company does not earn any profits or earns inadequate profits as contemplated under the provisions of Schedule V to the Companies Act, 2013, the Company may pay to the Managing Director, the above remuneration on the minimum remuneration by way of salary, Perquisites and Other terms & Conditions as specified above and subject to receipt of the requisite approvals.

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee of Directors) be and is hereby authorised to vary and/or revise the remuneration of Mr. Shalin Sudhakarbhair Patel as Chairman and Managing Director within the overall limits under the Act and to do all such acts, deeds and things and execute all such documents, instruments as may be necessary”.

8. To consider and if thought fit to pass with or without modification the following resolution as an Special Resolution for remuneration for remaining tenure of Shalin Bharatbhair Chokshi Whole Time Director of the Company :

“RESOLVED THAT pursuant to the provisions of Sections 196, 197 and 198 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (hereinafter referred to as the “Act”) and the Rules framed thereunder, (including any statutory modifications or re-enactment thereof, for the time being in force) and the Articles of Association of the Company and subject to such other approvals as may be necessary, the approval of the Members be and hereby accorded for the payment of the remuneration of Rs. 5.00 Lacs per month to Mr. Shalin Bharatbhair Chokshi (DIN: 00191903), Whole Time Director, for the remaining period namely , from October 1, 2020 to December 3, 2022”;

RESOLVED FURTHER THAT the terms of remuneration as set out in the Explanatory Statement of this Resolution shall be deemed to form part hereof and in the event of any inadequacy or absence of profits in any financial year or years, the aforementioned remuneration comprising salary, perquisites and

benefits approved herein be continued to be paid as minimum remuneration to the Whole Time Director, subject to such other approvals as may be necessary;

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee of Directors) be and is hereby authorised to vary and/or

revise the remuneration of Mr. Shalin Bharatbhai Chokshi as Whole Time Director within the overall limits under the Act and to do all such acts, deeds and things and execute all such documents, instruments as may be necessary”

9. To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution for grant of approval of related party transactions :

“RESOLVED THAT pursuant to the provisions of section 188 and other applicable provisions of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (including any amendment, modification, variation or re-enactment thereof for the time being in force), consent of the Members of the Company be and is hereby accorded to the Board of Directors (hereinafter referred to as “the Board” which term shall be deemed to include any Committee of the Board), to enter into contracts/ arrangements/ agreements/ transactions (including any modifications, alterations or amendments thereto) in the ordinary course of business and on arm’s length basis with related parties within the meaning of the Act and Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, as more particularly enumerated in the explanatory statement annexed to the Notice on such terms and conditions as may be agreed between the Company and its related party.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do or cause to be done all such acts, deeds, things, settle any queries, doubt that may arise with regard to any transactions with the related party, make such changes to the terms and conditions as may be considered necessary or desirable in order to give effects to this Resolution in the best interest of the Company.”

10. To consider and if thought fit to pass with or without modification the following resolution as an Special Resolution for appointment of Mr. Dipen Ashit Dalal as an Independent Director :

“RESOLVED THAT, pursuant to the provision of Section 149, 150 and 152 and other applicable provision, if any, of the Companies Act, 2013 and rules made there under read with Schedule IV of the Companies Act, Mr. Dipen

Ashit Dalal (DIN : 0009219731) who was appointed as an Additional Director with effect from 17th July, 2021 under Section 161 of the Companies Act 2013 be and is hereby appointed as Independent Director of the Company to hold office for a term up to five consecutive years commencing from 17th July, 2021 and shall not be liable to retire by rotation”

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**MANAGING DIRECTOR
Shalin Sudhakarbhair Patel
[DIN : 01779902]**

Notes:

1. An Explanatory Statement pursuant to Section 102 (1) of the Companies Act, 2013 (hereinafter referred to as the “Act”), in respect of businesses to be transacted at the Annual General Meeting (hereinafter referred to as “AGM”), as set out under Item No(s). 4 to 10 above and the relevant details of the Directors as mentioned under Item No (s). 2 above as required by Regulations 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 (hereinafter referred to as “Listing Regulations”) and as required under Secretarial Standards – 2 on General Meetings issued by the Institute of Company Secretaries of India, is annexed thereto.
2. A member entitled to attend and vote at the Annual General Meeting is entitled to appoint a proxy to attend and vote on a poll instead of himself /herself and the proxy need not be a member of the Company. The instrument appointing the proxy should, however, be deposited at the registered office of the Company not less than forty-eight hours before the commencement of the Annual General Meeting.
3. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder. The holder of proxy shall prove his identity

at the time of attending the Annual General Meeting. Attendance Slip, Proxy Form and the Route Map of the venue of the Meeting are annexed hereto.

4. Corporate members intending to send their authorized representatives to attend the meeting are requested to send certified copy of Board Resolution or other governing body authorizing their representatives to attend and vote on their behalf at the meeting.
5. Members / proxies / authorized representatives should bring their copy of the Annual Report and Accounts along with duly filled Attendance Slip enclosed herewith to attend the Meeting.
6. Members who hold shares in dematerialized form are requested to write their DP ID and Client ID Numbers and those who hold shares in Physical form are requested to write their Folio Number in the Attendance Slip for attending the Meeting.
7. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of Names will be entitled to vote.
8. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Companies Act, 2013 ('the Act') and the Register of Contracts or Arrangements in which Directors are interested, maintained under Section 189 of the Act, will be available for inspection by the members at the Annual General Meeting.
9. The Register of Beneficial Owners, Register of Members and Share Transfer Book of the Company shall remain closed from Saturday, 18th September, 2021 to Friday, 24th September, 2021 (both days inclusive) for the purpose of Annual General Meeting.
10. All documents referred to in the accompanying notice and explanatory statement are open for inspection at the registered office of the Company on all working days, except Saturday between 11:00 a.m. to 01:00 p.m. prior to the date of Annual General Meeting of the Company.
11. Any member desiring any clarification/explanation in respect of the information given in this annual report is requested to submit query to the company at least 10 days in advance before the meeting so as to enable the management to keep information ready.
12. SEBI has decided that securities of listed companies can be transferred only in dematerialised form April 01, 2019. In view of the above and to avail various benefits of dematerialisation, members are advised to dematerialise shares held by them in physical form.

13. To support the 'Green Initiative', Members who have not registered their e-mail addresses are requested to register the same with DPs or RTA of the Company.
14. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system will be provided by NSDL.
15. The Members of the company holding Shares as on Saturday, 20th August, 2021 (Cut-off date for entitlement of Annual Report), shall be eligible for receiving the Annual Report 2020-21 along with the notice of the Annual General Meeting, by electronic mode to all the members whose email addresses are registered with the Depository Participant(s).
16. Members can avail the nomination facility by filing Form No. SH-13, as prescribed under Section 72 of the Companies Act, 2013 and rule 19 (1) of the Companies (Share Capital and debentures) Rules 2014 with the Company. Blank forms will be supplied on request.
17. Members who hold shares in dematerialized mode are requested to intimate any changes pertaining with their bank account details, ECS mandates, nominations, change of address/name etc. to their Depository Participant. Changes intimated to the Depository Participant will then be automatically reflected in the Company's records which will help the Company and its Registrar & Share Transfer Agent to provide efficient and better service to the members. The e-voting period commences on Tuesday, the September 21, 2021 at 9:00 a.m. and ends on Thursday, September 23, 2021 at 5:00 p.m. During this period, members of the Company holding shares either in physical form or in dematerialized form, as on the Cut-off date i.e. Saturday, September 18, 2021, may cast their vote electronically. The members will not be able to cast their vote electronically beyond the date and time mentioned above and the e-voting module will be disabled by NSDL for voting thereafter. The voting rights of the members shall be in proportion to their share in the paid up equity share capital of the Company as on the Cut-off date i.e. Saturday, September 18, 2021. Once the vote on a resolution is cast by the member, he/she shall not be allowed to change it subsequently or cast the vote again.

18. The facility for voting through ballot papers will also be made available at the AGM and the members attending the AGM who have not already cast their votes by remote e-voting shall be able to exercise their right at the AGM through ballot process. The Members who have cast their votes by remote e-voting prior to the AGM may attend the AGM but shall not be entitled to cast their votes again.
19. If Members are opting for remote e-voting, they shall not vote by poll paper and vice versa. However, in case Members cast their vote both by poll paper and by remote e-voting, then voting done through remote e-voting shall prevail and voting done by poll paper will be treated as invalid.

The Scrutinizers shall immediately after the conclusion of the voting at the meeting, first count the votes of the valid poll paper cast at the 10th Annual General Meeting. They shall then proceed to unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company. The Scrutinizers thereafter shall submit their report to the Chairperson after completion of their scrutiny. The result of the voting will be announced within 2 working days of the conclusion of the 10th Annual General Meeting at the Registered Office of the Company.

The results declared along with the Scrutinizer's report shall be placed on the Company's website www.arveelabs.com and on the website of NSDL and shall also be intimated to the National Stock Exchange (NSE) where shares of the Company are listed.

Members who are holding shares in identical order of names in more than one folio are requested to send to the Company or RTA, the details of such folios together with the share certificates for consolidating their holdings in one folio.

A detailed list of instructions for e-voting is annexed to this Notice. Facility of Video Conferencing will be provided at the Venue, in case the number of members attending the AGM exceeds than permitted by the laws for the time being in force.

Instructions for e-voting

Pursuant to SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 9 December 2020 on “e-voting facility provided by Listed Companies”, e-voting process has been enabled to all the individual demat account holders, by way of single login credential, through their demat accounts/websites of Depositories/DPs in order to increase the efficiency of the voting process. Individual demat account holders would be able to cast their vote without having to register again with the e-voting service provider (ESP) thereby not only facilitating seamless authentication but also ease and convenience of participating in e-voting process.

Shareholders are advised to update their mobile number and e-mail id with their DPs in order to access e-voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

The Electronic voting particulars are set out below:

EVEN (E-VOTING EVENT NUMBER)
116809

The detailed instructions for e-voting are as follows:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode	1. If you are already registered for NSDL IDeAS facility , please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Services is

with NSDL	launched, click on the “Beneficial Owner” icon under “Login” which is available under “IDeAS” section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on options available against company name or e-Voting service provider - NSDL and you will be re-directed to NSDL e-Voting website for casting your vote during the remote e-Voting period. 2. If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS” Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on options available against company name or e-Voting service provider - NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.
Individual Shareholders holding securities in demat mode with CDSL	1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. 2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote. 3. If the user is not registered for Easi/Easiest, option to register is available at

	https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Once login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on options available against company name or e-Voting service provider-NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 or 022-23058542-43

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can user your

existing password to login and cast your vote.

- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered**
- 6. If you are unable to retrieve or have not received the “ Initial password” or have forgotten your password:
 - a) Click on “[Forgot User Details/Password?](#)”(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) [Physical User Reset Password?](#)” (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
- 7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
- 8. Now, you will have to click on “Login” button.
- 9. After you click on the “Login” button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of AADHAR Card) by email to compliance@arveelabs.com
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of AADHAR Card) to compliance@arveelabs.com If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

CONTACT DETAILS:

Company	:	ARVEE LABORATORIES (INDIA) LIMITED Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon - Bopal Road, Ambli Ahmedabad, Gujarat - 380058 compliance@arveelabs.com CIN : L24231GJ2012PLC068778 www.arveelabs.com Tel : 91- 2717-430479
Registrar & Transfer Agents	:	BIGSHARE SERVICES PRIVATE LIMITED 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400059 Tel: +91 22 62638200 Fax: +91 22 62638299
E-voting Agency	:	National Securities Depository Limited Email : evoting@nsdl.co.in Phone : 1800-222-990 (Toll Free)
Scrutinizer	:	Jalan Alkesh & Associates Practicing Company Secretary E-mail : jalanalkesh@gmail.com

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to jalanalkesh@gmail.com with a copy marked to evoting@nsdl.co.in
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the **“Forgot User Details/Password?”** or **“Physical User Reset Password?”** option available **on** www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: **1800-1020-990/1800-2244-30** or send a request at evoting@nsdl.co.in

ANNEXURES TO THE NOTICE

ANNEXURE A

Details of the Director retiring by rotation and seeking Re-appointment at the Annual General meeting pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and Secretarial Standard: 2 (SS:2) issued by ICSI and approved by the Central Government.

Name of the Director	Shalin Bharatbhai Chokshi
Father's Name	Bharatbhai Chokshi
Date of Birth	16/10/1984
Qualification	He is a graduate in commerce and holds a degree in Masters of Professional Accounting, Monash University, Australia.
Date of Joining the Board of Director of the Company	27/01/2012
Number of Shares held in the Company	13,38,000
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	Nil
Other Chairmanship / Membership of Committees of Board of other Companies	Nil
Specific Functional Area	He has been pivotal in bringing new international raw material suppliers to the Company which has proved to be highly cost beneficial to the company. At the same time he has identified key consumers for Company's products in the International market. He closely monitors Company affairs and its functions
Relationship with Directors / inter-se KMP	Nil
Experience	Mr. Shalin Bharat Chokshi, aged 36 Years, is the Promoter and Whole Time Director of our

	Company. He is a graduate in commerce and holds a degree in Masters of Professional Accounting, Monash University, Australia. He has 11 years of experience in sales and international business. He has worked with Companies like B Chokshi Chem Private Limited, where he was responsible for developing new clients as well as suppliers. He has been instrumental in identifying new suppliers to strategically improve the Company supply chain.
Terms and Conditions of appointment	As per the agreement entered with effect from 4 th December, 2017. He is appointed on salary of Rs. 1.00 Lacs per month with effect from 4 th December, 2017. However with effect from 1 st October, 2020 his salary has been increased to Rs. 5.00 Lacs per month.
Remuneration sought to be paid and last drawn	Rs. 3672946 paid during the year 2020 – 2021. It is proposed to pay remuneration of Rs. 5.00 lacs with effect from 1 st October, 2020.
Number of meeting of Board of Directors attended during the year	10

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad
Dated: 17th July, 2021

Sd/-

MANAGING DIRECTOR
Shalin Sudhakarbhair Patel
[DIN : 01779902]

**Explanatory Statement pursuant to Section 102 of the Companies Act, 2013
in respect of item No. 4 to 10 is as under:**

Item No. 4

KCJM & Associates, Chartered Accountants have vide their letter dated 17th July, 2021 tendered their resignation as auditors with effect from 18th July, 2021. The Board of Directors in their meeting held on 17th July, 2021 have accepted the same.

Based on the recommendation of Audit Committee, the Board of Directors in their meeting held on 17th July, 2021 have appointed Jaimin Deliwala & Co., Chartered Accountants, Ahmedabad to hold office from 18th July, 2021 till the conclusion of annual general meeting for the year ended on 31st March, 2021 to fill the casual vacancy caused by the resignation of KCJM & Associates.

The Company has received consent letter and eligibility letter from Jaimin Deliwala & Co., Chartered Accountants, Ahmedabad to act as statutory auditors along with a confirmation that if their appointment is made it will be within the limits prescribed by the provision of Companies Act, 2013.

None of the Directors or Key Managerial Personnel are interested in the proposed resolution

The Board recommends the passing of resolution as mentioned in item no. 4

Item No. 5

The Board of Directors of the Company at its meeting held on February 12, 2021 appointed Mrs. Neetu Rishi Jalan as an Additional Director of the Company in the capacity of Independent Director for a term of 5 years with effect from February 12, 2021, subject to the approval of the Members of the Company.

In terms of section 160 of the Companies Act, 2013, the Nomination and Remuneration Committee and the Board have recommended the appointment of Mrs. Neetu Rishi Jalan as an Independent Director pursuant to the provisions of Sections 149 and 152 of the Companies Act, 2013. The Company has also received a notice in writing from a member proposing the candidature of Mrs. Neetu Rishi Jalan to be appointed as Director of the Company.

The Company has received a declaration from Mrs. Neetu Rishi Jalan confirming that she meets the criteria of independence under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, the Company has also received Mrs. Neetu Rishi Jalan consent to act as a Director in terms of section 152 of the Companies Act, 2013 and a declaration that she is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013.

In the opinion of the Board, Mrs. Neetu Rishi Jalan fulfils the conditions specified in

the Companies Act, 2013 and rules made thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for her appointment as an Independent Director of the Company and he is independent of the management except Mrs. Neetu Rishi Jalan, being the appointee, or her relatives, none of the Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested financially or otherwise, in the resolution set out at Item No. 5.

The Board of Directors recommends the resolution in relation to appointment of Mrs. Neetu Rishi Jalan as an Independent Director of the Company, as set out in Item No. 5 for approval of the members by way of a Special Resolution. Additional Information required pursuant to SS – 2 is as under:

Name of the Director	Neetu Rishi Jalan
Father's Name	Shivkumar Daulatram Gupta
Date of Birth	03/07/1982
Qualification	Bachelor of Arts
Date of Joining the Board of Director of the Company	12 th February, 2021
Number of Shares held in the Company	Nil
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	Nil
Other Chairmanship / Membership of Committees of Board of other Companies	In addition to this Company, Mrs. Neetu Jalan is an independent director on the Board of Directors of H.M. Electromech Limited. Neetu Jalan is also a member of the Audit Committee of H.M. Electromech Limited.
Specific Functional Area	Neetu Jalan has experience in the field of the administration of affairs of the Company. Neetu Jalan is an independent director on the Board of Directors of H.M. Electromech Limited. Neetu Jalan is also a member of the Audit Committee of H.M. Electromech Limited.
Relationship with Directors / inter-se KMP	None
Experience	Neetu Jalan has experience in the field of the administration of affairs of the Company

Terms and Conditions of appointment	Upton 5 years commencing from date of appointment i.e. 12 th February, 2021.
Remuneration sought to be paid and last drawn	Nil. However the Board of Directors is at liberty to pay remuneration within the limits of Companies Act 2013.
Number of meeting of Board of Directors attended during the year	1

Item No. 6

Vide Companies (Amendment) Act, 2017, Section 185 of the Act has been amended and the same was notified by the Ministry of Corporate Affairs on 7th May, 2018. In terms of the amended Section 185 of the Act, a company may advance any loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any person in whom any of the Director of the Company is interested subject to the condition that approval of the shareholders of the Company is obtained by way of Special Resolution and requisite disclosures are made in the explanatory Statement and such loans are utilized by the borrowing company for its principal business activities only.

In view of the above and in line with the approval of the shareholders accorded under section 186 of the Act & as an abundant caution, the Board at its meeting held on July 15, 2021 decided to seek approval of the shareholders pursuant to the amended provisions of Section 185 of the Act to advance any loans, Investment and/or giving of security and/or guarantee for the loans availed or to be availed by the following body corporates one in which one or more Director(s) of the Company are interested, either directly or indirectly subject to the maximum amount of Loans and/or guarantee and/or Security of an aggregate amount not exceeding Rs. 10 crores (Rupees Ten Crores only) at any time.

a. Arvee Speciality Chemicals Private Limited

Mr. Shalin Patel and Mr. Shalin Chokshi, Director of the Company are also the Directors of Arvee Speciality Chemicals Private Limited. Mr. Shalin Chokshi holds 25% of the Paid up Capital. Shalin Chokshi HUF holds 25% of the Paid up Capital and Shalin Patel HUF holds 25% of Paid up Capital and Chandrabalaben Patel (Mother of Shalin Patel) holds 25% of Paid up Capital of Arvee Speciality Chemicals Private Limited.

The proposed transaction is within the limits of approvals taken earlier under Section 186 of the Companies Act, 2013. None of Directors other than Mr. Shalin Patel and Mr. Shalin Chokshi are interested in the proposed resolution. None of Key Managerial Personnel are interested in the proposed resolution.

Item No. 7

The Board of Directors at its meeting held on 5th November, 2020 and pursuant to the recommendation of Nomination and Remuneration Committee have decided to increase the remuneration of Mr. Shalin Sudhakarbhair Patel with effect from 1st October, 2020. It is proposed to increase the monthly remuneration from present Rs. 1.00 Lacs to Rs. 5.00 Lacs for the remaining tenure till 3rd December, 2022. Mr. Shalin Sudhakarbhair Patel is a Director of the Company since 1.4.2014. He became Managing Director of the Company with effect from 4th December, 2017.

Pursuant to Section 190 of the Companies Act, 2013 a copy of the Agreement dated 4th December, 2017 and 18th December, 2020 executed by the Company with the Chairman and Managing Director is kept and available for inspection at the Registered Office of the Company on all working days (except Saturdays, Sundays and Public Holidays) between 11.00 a.m. to 1.00 p.m. up to the date of this Annual General Meeting ("AGM") at the Registered Office of the Company.

Mr. Shalin Sudhakarbhair Patel is the son of Mr. Sudhakarbhair Chhotabhai Patel having Director Identification Number 01779902. He has attended all the 10 Board Meetings of the Company held during the year. Mr. Shalin Sudhakarbhair Patel is not related to any other Director or Key Managerial Personnel. Mr. Shalin Sudhakarbhair Patel was born on 23rd November, 1974. Mr. Shalin Patel is also a Director in Shree Rama Multi-Tech Limited (a Listed Company) and 2 Private Limited Company namely 1. Arvee Speciality Chemicals Private Limited and 2. Applitech Infotech Private Limited. He is also a member of Audit Committee, Stakeholders Committee and Nomination and Remuneration Committee of Shree Rama Multi-Tech Limited.

Mr. Shalin Sudhakarbhair Patel, aged 46 Years, is the Promoter and Managing Director of our Company. He holds a degree in Master of Business Administration from Cleveland State University – USA. He has experience of more than 20 years in project management for technically based industries. His experience includes engineering and design of instrumentation and control systems, computer networks and software development for biopharmaceutical, power distribution, chemical and plastics industries. He has worked with companies like Applied Biosystems, ISO-New England, and National Grid. Currently, he is looking after purchase, sales, research & development and overall business development of the Company.

Since in terms of Schedule V of the Companies Act, 2013, the effective Capital of your Company is more than Rs. 5.00 Crores but less than 100.00 Crores, the Company can pay minimum remuneration of Rs. 5.00 Lacs per month to one managerial personnel.

The details of shares held by him and his relatives are as under:

Sr. No.	Name of Shareholder	Number of Shares held	% of total paid up Capital
----------------	----------------------------	------------------------------	-----------------------------------

1.	Shalin Sudhakarbhair Patel	33,80,000	30.67
2.	Sudhakarbhair Chhotabhair Patel	6,62,000	6.01
3.	Sudhakar Chhotabhair Patel HUF	2,000	0.02
4.	Chandrabalben Patel	2,000	0.02
5.	Shalinbhair Sudhakarbhair Patel HUF	2,000	0.02
6.	Khushbuben S Patel	2,000	0.02

Mr. Shalin Sudhakarbhair Patel satisfies all the conditions as set out in Part I of Schedule V as also under sub section 13 of Section 196 of the Companies Act, 2013 for being eligible to be appointed as a Managing Director of the Company. He is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013.

The Board of Directors are of the opinion that the re-appointment of Mr. Shalin Sudhakarbhair Patel as the Managing Director is in the best interest of the Company and accordingly, recommend the Special resolution set out in Item No. 7 for approval of the members. Hence the said Special Resolution is recommended for your approval.

None of the Directors, Key Managerial Personnel of the Company and their relatives other than Mr. Shalin Sudhakarbhair Patel, are in any way concerned or interested, financial or otherwise, in the said Resolution.

Item No. 8

The Board of Directors at its meeting held on 5th November, 2020 and pursuant to the recommendation of Nomination and Remuneration Committee have decided to increase the remuneration of Mr. Shalin Bharatbhair Chokshi with effect from 1st October, 2020. It is proposed to increase the monthly remuneration from present Rs. 1.00 Lacs to Rs. 5.00 Lacs for the remaining tenure till 3rd December, 2022.

Mr. Shalin Bharatbhair Chokshi is a Director of the Company since 27.1.2012. He became Whole Time Director of the Company with effect from 4th December, 2017.

Mr. Shalin Bharatbhair Chokshi, aged 36 Years, is the Promoter and Whole- Time Director of our Company. He is a graduate in commerce and holds a degree in Masters of Professional Accounting, Monash University, Australia. He has 7 years of experience in sales and international business. He has worked with Companies like B Chokshi Chem Private Limited, where he was responsible for developing new clients as well as suppliers. He has been instrumental in identifying new suppliers to strategically improve the Company supply chain. He has been pivotal in bringing new international raw material suppliers to the Company which has proved to be highly cost beneficial to the company. At the same time he has identified key consumers for Company's products in the International market. He closely monitors Company affairs and its functions.

Disclosures made for item no. 2 of the Notice regarding Shalin Bharatbhair Chokshi may be regarded as disclosures for this agenda item also. Pursuant to Section 190 of the Companies Act, 2013 a copy of the Agreement dated 4th December, 2017 and

18th December, 2020 executed by the Company with the Whole Time Director is kept and available for inspection at the Registered Office of the Company on all working days (except Saturdays, Sundays and Public Holidays) between 11.00 a.m. to 1.00 p.m. up to the date of this Annual General Meeting (“AGM”) at the Registered Office of the Company.

Since in terms of Schedule V of the Companies Act, 2013, the effective Capital of your Company is more than Rs. 5.00 Crores but less than 100.00 Crores, the Company can pay minimum remuneration of Rs. 5.00 Lacs per month to one managerial personnel.

The details of shares held by him and his relatives are as under:

Sr. No.	Name of Shareholder	Number of Shares held	% of total paid up Capital
1.	Shalin Bharat Chokshi	13,38,000	12.14
2.	Bharat Rasiklal Chokshi	13,70,000	12.43
3.	Saumil Bharatbhai Chokshi	13,38,000	12.14
4.	Forum Saumil Chokshi	2,000	0.02
5.	Kavita Shalin Chokshi	2,000	0.02

Mr. Shalin Bharatbhai Chokshi satisfies all the conditions as set out in Part I of Schedule V as also under sub section 13 of Section 196 of the Companies Act, 2013 for being eligible to be appointed as a Whole Time Director of the Company. He is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013.

The Board of Directors are of the opinion that the re-appointment of Mr. Shalin Bharatbhai Chokshi as the Whole Time Director is in the best interest of the Company and accordingly, recommend the Special resolution set out in Item No. 8 for approval of the members. Hence the said Special Resolution is recommended for your approval.

None of the Directors, Key Managerial Personnel of the Company and their relatives other than Mr. Shalin Bharatbhai Chokshi, are in any way concerned or interested, financial or otherwise, in the said Resolution.

Item No. 9

Pursuant to Section 188 of the Companies Act, 2013, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, the Company is required to obtain consent of Board of Directors and prior approval of the members by way of Ordinary Resolution, in case certain transactions with related parties exceeds such sum as is specified in the Rules made thereunder from time to time. The aforesaid provisions are not applicable in respect of transactions entered into by the Company in the ordinary course of business on an arm’s length basis.

However, pursuant to Regulation 23 of the Securities Exchange Board of India

(Listing Obligations and Disclosure Requirements) Regulations, 2015, approval of the members through Ordinary Resolution is required for related party transactions, even if they are entered into in the ordinary course of business and on arm's length basis. For this purpose, a transaction is considered material, if the transaction/transactions to be entered into individually or taken together with previous transactions during a financial year exceed 10% of the annual turnover of the Company, as per the last audited financial statements of the Company.

All the Related Party Transactions entered / proposed to be entered into by the Company are at arm's length basis and in the ordinary course of business and approval of the Audit Committee / Board is obtained, wherever required.

The Company has existing transactions with its related party, which is in the ordinary course of business and at arm's length basis. However, the value of transactions with related party in respect of upcoming financial years and the estimated value of transaction are likely to exceed 10% of the annual turnover of the Company, based on the audited financial statements for year ended 31st March, 2021.

Accordingly, on recommendation of the Audit Committee and Meeting of the Board of Directors held on 17th July, 2021 approved related party transactions and it is proposed to seek approval of the members by way of Ordinary Resolution under Section 188 of the Companies Act, 2013, the Companies (Meeting of Board and its Power) Rules, 2014 and SEBI (LODR) Regulations, 2015 to enable the Company to enter into following related party transactions in one or more tranches.

The particulars of the contract / transactions with its related party are as under:

Name of the Related Party	Nature of Relationship	Nature of Transaction proposed to be entered
Arvee Speciality Chemicals Private Limited	A Company in which Mr. Shalin Chokshi and Shalin Patel are interested directly or indirectly. Mr. Shalin Chokshi holds 25% of the Paid up Capital. Shalin Chokshi HUF holds 25% of the Paid up Capital and Shalin Patel HUF holds 25% of Paid up Capital and Chandrabalaben Patel (Mother of Shalin Patel) holds 25% of Paid up Capital	Sale, Purchase or supply of any goods or material or Services

The Aggregate value of transactions of the Company with per related party does not

exceed 50 Crore Rupees per year.

Mr. Shalin Patel and Mr. Shalin Chokshi are deemed to be interested in the proposed resolution. Other than this none of other directors, Key Managerial Personnel or their relatives are directly or indirectly concerned or interested, financially or otherwise, except to the extent of his/ her respective shareholding, if any, in the Company, in the resolution set out in item No. 9 of the Notice.

The Board recommends the Ordinary Resolution at Item No. 9 of the Notice for approval of the Members.

Item No. 10

The Board of Directors of the Company at its meeting held on July 17, 2021 appointed Mr. Dipen Ashit Dalal as an Additional Director of the Company in the capacity of Independent Director for a term of 5 years with effect from July 17, 2021, subject to the approval of the Members of the Company.

In terms of section 160 of the Companies Act, 2013, the Board Governance, Nomination and Compensation Committee and the Board have recommended the appointment of Mr. Dipen Ashit Dalal as an Independent Director pursuant to the provisions of Sections 149 and 152 of the Companies Act, 2013. The Company has also received a notice in writing from a member proposing the candidature of Mr.

Dipen Ashit Dalal to be appointed as Director of the Company. The Company has received a declaration from Mr. Dipen Ashit Dalal confirming that he meets the criteria of independence under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, the Company has also received Mr. Dipen Ashit Dalal consent to act as a Director in terms of section 152 of the Companies Act, 2013 and a declaration that he is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013.

In the opinion of the Board, Mr. Dipen Ashit Dalal fulfils the conditions specified in the Companies Act, 2013 and rules made thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for his appointment as an Independent Director of the Company and he is independent of the management.

Except Mr. Dipen Ashit Dalal, being the appointee, or his relatives, none of the Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested financially or otherwise, in the resolution set out at Item No. 10.

The Board of Directors recommends the resolution in relation to appointment of Mr. Dipen Ashit Dalal as an Independent Director of the Company, as set out in Item No. 10 for approval of the members by way of a Special Resolution. Additional Information required pursuant to SS – 2 is as under:

Name of the Director	Dipen Ashit Dalal
Father Name	Ashit Haridas Dalal
Date of Birth	24 th June, 1992
Number of Shares Held in the Company	Nil
Date of Joining the Board of Directors	17 th July, 2021
Qualification	B.Com, LLB., Company Secretary
Terms and conditions of Appointment	Up to 5 years from the date of appointment i.e. 17 th July, 2021
Name of other listed Entity in which he / she holds Directorship and of Committees of Listed Entities	Director in One Listed entity namely Frontline Corporation Limited. Membership in other listed entities Nil
Number of Meetings attended during the year	Not Applicable
Relationship with Directors / Inter se KMP	Nil
Experience	Mr. Dipen Dalal has good experience in the field of legal, secretarial and accounting.
Remuneration Paid and sought to be drawn	Remuneration Paid Nil. Proposed to be paid Nil

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**MANAGING DIRECTOR
Shalin Sudhakarbhair Patel
[DIN : 01779902]**

PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 read with Rule 19(3) of the companies (Management and Administration) Rules, 2014]

ARVEE LABORATORIES (INDIA) LIMITED

Registered Office: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon - Bopal Road,
Ambli, Ahmedabad - 380 058, Gujarat, India

Telephone: +91-79-26749036/37/38 Fax No. +91-79-26742600

Email: compliance@arveelabs.com, www.arveelabs.com

CIN: L24231GJ2012PLC068778

Name of the Member(s):

Registered address:

E-mail Id:

Folio No./ Client ID:

DP Id:

I/We being the member(s) of _____ shares of the above named Company hereby appoint:

(1) Name: _____

Address: _____

E-mail Id: _____ or failing him;

(2) Name: _____

Address: _____

E-mail Id: _____ or failing him;

(3) Name: _____

Address: _____

E-mail Id: _____ or failing him;

as my/our proxy to attend and vote (on a poll) for me /us and on my/our behalf at the 10th Annual General Meeting of the Company to be held at 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad - 380 058, Gujarat, at 11.300 a.m. on Friday, 24th September, 2021 and at any adjournment thereof in respect of such resolution as are indicate below:

Resolution No	Particulars of Resolution	Voting	
		For	Against
	ORDINARY BUSINESS		
1	Adoption of Audited Accounts for the year ended on 31 st March, 2021 and the Reports of the Board of Directors and Auditors thereon. (Ordinary Resolution)		
2	To reappoint a Director in place of Mr. Shalin Bharatbhai Chokshi who retires by rotation and being eligible seeks re-appointment. (Ordinary Resolution)		
3	Appointment of Auditors (Ordinary Resolution)		
	SPECIAL BUSINESS		
4	Appointment of Statutory Auditors to fill Casual Vacancy (Ordinary Resolution)		
5	Appointment of Mrs. Neetu Rishi Jalan as an Independent Director (Special Resolution)		
6	Approval for grant of loans, or providing Security or Guarantee for the loans availed by other entities in which the Directors of the Company are interested. (Special Resolution)		
7	Approval for remuneration for remaining tenure of Shalin Sudhakarbhai Patel Managing Director of the Company (Special Resolution)		
8	Approval for remuneration for remaining tenure of Shalin Bharatbhai Chokshi Whole Time Director of the Company (Special Resolution)		
9	For grant of approval of related party transactions (Ordinary Resolution)		
10	for appointment of Mr. Dipen Ashit Dalal as an Independent Director (Special Resolution)		

Signed this _____ day of _____ 2021

Signature of the member

Signature of proxy holder

Affix Revenue
Stamp

Notes:

1. This form, in order to be effective, should be duly stamped, completed, signed and deposited at the registered office of the Company, not less than 48 hours before the Annual General Meeting.

2. It is optional to indicate your preference. If you leave the 'for', or 'against' column blank against any or all of the resolutions, your proxy will be entitled to vote in the manner as he/she may deem appropriate.

ARVEE LABORATORIES (INDIA) LIMITED

DIRECTOR`S REPORT

To
The Members of,
ARVEE LABORATORIES (INDIA) LIMITED

Your Directors have pleasure in presenting the 10th Annual Report on the business and operations of the Company together with Audited Statement of Accounts for the year ended on 31st March 2021 with Auditor's Report thereon.

Financial Highlights

	(Rs. In Lacs)	
Particulars	2020 - 2021	2019 - 2020
Revenue from Operations	4737.50	4541.87
Other Income	58.48	34.60
Total Revenue	4795.98	4576.47
Depreciation	240.66	228.90
Financial Expenses	57.64	98.77
Profit before Tax	364.14	309.05
Tax Expense -	96.40	79.16
Profit After Tax	267.73	222.89
Add : Balance Brought forward from the previous year	580.48	350.58
Balance carried to the next year	848.22	580.48

The above performance is based on standalone basis. Consolidated figures are not applicable.

State of Affairs:

Turnover of the Company has increased marginally. However profit after tax has increased by 16.46%. Considering the covid situation during the year under review, your Directors are hopeful of Company better performance in future.

The Company is taking all the possible steps to increase the profitability.

Transfer to Reserves (i.e. Other Equity):

During the year under review, your Company has utilized a sum of Rs. 551.00 Lacs from the Security Premium Reserve for the issue of bonus shares. The Opening Balance of Security Premium Reserve stands at Rs. 744.60 Lacs whereas the closing balance of Security Premium Reserve stands at Rs. 193.60 Lacs.

The Opening Balance of Retained Earnings stands at Rs. 580.48 Lacs. During the year under review whole of the Profit after tax of Rs. 267.73 Lacs has been transferred to Retained Earnings. The Closing Balance of Retained Earnings stands at Rs. 848.22 Lacs.

Dividend:

In order to conserve resources, your Directors do not recommended dividend for the year 2020-21 on Equity Shares of the Company.

Details regarding Energy Conservation:

Pursuant to Rule 8 (3) of Companies (Accounts) Rules, 2014, the Board of Directors hereby state as under declare that.

A. CONSERVATION OF ENERGY:

Power & Fuel Consumption:	Current Year
Electricity:	
i) Power Consumed(Purchased):	
(a) Units	14,06,175 units
(b) Amount	1,02,60,509.87
(c) Units/per liter of Diesel Oil	--
(d) Cost per unit (Rs.)	7.30/Unit
ii) Own Generation:	
(a) Units	--
(b) Amount	--
(c) Units/per liter of Diesel Oil	--
(d) Cost per unit (Rs.)	--
iii) Windmill Turbine:	
(a) Units	--
(b) Amount	--

Steps taken or impact on conservation of energy.

In line with the Company's commitment towards conservation of energy, all units continue with their efforts aimed at improving energy efficiency through innovative measures to reduce wastage and optimize consumption. Some of the measures taken by the Company in this direction at its units located at areas under:

- a. We have made optimum use of electrical motors and day light resources at plant.
- b. Installation of LEDs at several locations.

The steps taken by the company for utilising alternate sources of energy: **NIL**

There was no capital investment on energy conservation equipment.

Details regarding Technology Absorption:

Pursuant to Rule 8 (3) of Companies (Accounts) Rules, 2014, the Board of Directors hereby declare that there are no particulars to report for Technology Absorption. However the Company takes help of the technical consultants from time to time.

Details regarding Foreign Exchange Earnings and Outgo:

The details regarding foreign exchange earnings and outgo are provided in the note no. 38 to the financial Statement. Members are requested to refer the same.

Disclosure of Directors Responsibility Statement:

As required u/s 134 (5) of the Companies Act, 2013 the Directors hereby state and confirm:

- i. In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any.
- ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year as on 31/03/2021 and of the profit of the company for that period.
- iii. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.
- iv. The Directors have prepared the annual accounts on a going concern basis.
- v. The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- vi. The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Listing:

The Equity Shares of your Company were listed on Emerge Platform of National Stock Exchange of India Limited. However with effect from 22nd March, 2021 the Shares of the Company are traded on Capital Market Segment (Main Board) of the National Stock Exchange of India Limited. The Company has paid necessary listing fees for the year 2021 – 2022.

Details of Material Changes and Commitments, Occurred during the Period affecting financial position of the Company:

During the year under review there were no significant and material orders passed by any Regulators or Court or Tribunals which may have impact on the going

concern status. No order has been passed by any Regulators or Court or Tribunals which may have impact on the Company's operation in future. Further there is no material change and commitments occurred subsequent to the Balance sheet till date of report.

Particulars of Loans, Guarantees and Investments under Section 186 of the Companies Act, 2013:

The Company has not provided any guarantee or provided any Security to any Person for the loans availed by others. The details regarding the Loans and Advances, Investments, if any, are provided in the Balance Sheet and notes to the Balance Sheet.

Particulars of Contracts or Arrangements with Related Parties under Section 188 of the Companies Act, 2013:

All contracts / arrangements / transactions, if any, entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company has not entered into transactions with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions. The Policy for determination of Material Related party transaction is available at http://arveelabs.com/doc/OTHER_POLICIES.pdf

No advance is paid to any related party (other than loans and advances) for entering any transaction. No Bad Debts of related parties. . There being no 'material' RPTs as defined under regulation 23 of Listing Regulations, 2015, there are no details to be disclosed in Form AOC-2 in this regard.

The details of the related party transactions are disclosed in note 35 to the financial statement which sets out related party disclosures.

Disclosure of Companies covered under Section 178 (1) on Directors appointment and Remuneration including matters referred under Section 178 (3) of Companies Act, 2013 and Details of Statement indicating manner in which formal annual evaluation made by Board of its Performance and of its Committees and individual Directors:

The Company has devised a Policy for Directors; appointment and remuneration including criteria for determining qualifications, performance evaluation and other matters of Independent Directors, Board, Committees and other individual Directors which include criteria for performance evaluation of both non-executive directors and executive directors.

The Company's Nomination & Remuneration policy which includes the Director's appointment & remuneration and criteria for determining qualifications, positive attributes, independence of the Director & other matters is available on the website of the Company at the link www.arveelabs.com. Nomination and Remuneration Policy is annexed and marked as Annexure I

Declaration by Independent Directors:

The Independent Directors of the Company namely Vishal Nitin Mehta, Chandrakala Ashok Bhatt and Parag Manubahi Shah (w.e.f. 27th June 2020), Mrs. Neetu Rishi Jalan (w.e.f. 12th February, 2021) have confirmed to the Board that they meet the criteria of independence as specified under Section 149 (6) of the Companies Act, 2013 and they qualify to be independent directors. They have also confirmed that they meet the requirements of independent directors as specified in the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Share Capital:

During the year under review the Company has issued bonus shares in ratio of 1:1. Accordingly the Share Capital of the Company has been increased from Rs. 551.00 Lacs to 1102.00 Lacs.

Issue of Equity Shares with Differential Rights:

Details required to be stated as per Rule 4 (4) of Companies (Share Capital and Debenture Rules) 2014 is not applicable.

Disclosure regarding Employee Stock Options:

Details required to be given as stated in Rule 12 (19) Companies (Share Capital and Debenture Rules) 2014 is not applicable.

Disclosure regarding Sweat Equity Shares:

Details required to be given as stated in Rule 8 (13) Companies (Share Capital and Debenture Rules) 2014 is not applicable.

Auditors and Audit Report:

KCJM & Associates, Chartered Accountants, Ahmedabad vide their letter dated 17th July, 2021 have tendered resignation to be effective from 18th July, 2021. The Board has decided to appoint M/s. Jaimin Deliwala & Co, Chartered Accountant to hold office as Statutory Auditor till the conclusion of forthcoming annual general meeting. Further the Board has decided to appoint M/s. Jaimin Deliwala & Co, Chartered Accountant as Statutory auditors for a period of five years including for the financial year 2021 – 2022, subject to the approval of Shareholders in general meeting.

Further Board has also sought the approval of members for filing the Casual Vaccancy as described in the notice of annual general meeting.

There is no qualification or adverse remarks made by the auditors in their report.

Internal Audit:

Your Company has appointed M/s. Keval Ponkiya & Associates, Chartered Accountants as internal auditors.

Cost Audit and Cost Records:

The Company has maintained adequate Cost records required to be maintained in terms of the Companies Act, 2013. Cost Audit provisions are not applicable to the Company.

Disclosure of Risk Management Policy:

The Company has a structured risk management policy. The Risk management process is designed to safeguard the organization from various risks through adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in order to minimize its impact on the business. The potential risks are inventorised and integrated with the management process such that they receive the necessary consideration during decision making.

SECRETARIAL AUDIT

The Company has obtained a Secretarial Audit Report M/s. Jalan Alkesh & Associates, Company Secretary in Practice to conduct the secretarial audit for the financial year 2020-21. Secretarial Audit is attached and marked as Annexure II. In the opinion of the Board there is no qualification or adverse remarks.

Secretarial Compliance Report pursuant to Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 is annexed to the Board Report and marked as Annexure III

In the opinion of the Board there is no qualification or adverse remarks.

Board Meetings:

During the year under review, 10 (Ten) Board meetings were held. The dates of Board meetings and attendance details are as under:

Sr. No.	Date of Board Meeting	No. of Directors entitled to attend	No. of Directors who have attended the meeting	Name of the Director who Attended
1	27 th June, 2020	4	4	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Vishal Nitin Mehta
2	29 th June, 2020	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
3	24 th August, 2020	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat

				Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
4	10 th October, 2020	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
5	15 th October, 2020	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
6	24 th October, 2020	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
7	5 th November, 2020	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
8	8 th February, 2021	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt

				4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
9	12 th February, 2021	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta
10	5 th March, 2021	6	6	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Parag Manubhai Shah 5. Mr. Vishal Nitin Mehta 6. Mrs. Neetu Rishi Jalan

In respect of the above board meetings adequate notice was given to all the Directors together with the agenda. The gap between two Board meetings does not exceed 120 days. Independent Directors meeting was held on 24th August, 2020.

Corporate Governance:

Since the Company securities were listed on emerge platform of NSE, by virtue of Regulation 15 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the compliance of corporate governance provisions as specified in regulation 17 to 27 and clauses (b) to (i) of sub – regulation (2) of Regulation 46 and para C, D and E of Schedule V were not applicable to the Company. However with effect from 22nd March, 2021 the securities of the Company are available for trading on Capital Market Segment (Main Board) and consequently with effect from 22nd March, 2021 the provision of Corporate Governance became applicable. The report on Corporate Governance is provided in **Annexure IV**.

Management Discussion and Analysis Report:

Management Discussion and Analysis Report as required under Regulation 34 and Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith and marked as **Annexure V**.

Certificate on Corporate Governance Report:

A Certificate by Practicing Company Secretary for Corporate Governance Report is enclosed herewith and marked as **Annexure VI**.

Code of Conduct:

The Board of Directors has already adopted the Code of Ethics and Business Conduct for the Directors and Senior Management personnel. This code is a comprehensive code applicable to all Directors, Executive as well as Non – executive and members of the Senior Management. The Code has been circulated to all the members of the Board and Senior Management Personnel and compliance of the same has been affirmed by them.

A declaration given by the Managing Director is given below:

The Company has obtained from all the members of the Board and Senior Management Personnel of the Company, affirmation that they have complied with the Code of Ethics and Business Conduct framed for Directors and Senior Management Personnel in respect of the financial year 2020-2021.”

The company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company and can be accessed at www.arveelabs.com

Voluntary Revision of Financial Statements / Board Report:

There was no voluntary revision of financial statements or Board Report during the financial year.

Dematerialization of Shares:

100% Equity Shares of the Company are in Demat form.

Policies:

Various policies required under the provision of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 are adopted and uploaded on the website of the Company namely www.arveelabs.com

COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND GENERAL MEETINGS:

During the year under review, the Company has duly complied with the applicable provisions of the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India (ICSI).

Corporate Social Responsibility:

The Company do not fall under the Criteria of Section 135 of the Companies Act, 2013.

Investor Education and Protection Fund:

No amount was required to be transferred to Investor Education and Protection Fund.

Disclosure under Rule 8 (5) of Companies Accounts Rules, 2014:

a) Disclosure of financial Summary / Highlights:

(Rs. In Lacs)

Particulars	2020 – 2021	2019 - 2020
Revenue from Operations	4737.50	4541.87
Other Income	58.48	34.60
Total Revenue	4795.98	4576.47
Depreciation	240.66	228.90
Financial Expenses	57.64	98.77
Profit before Tax	364.14	309.05
Tax Expense -	96.40	79.16
Profit After Tax	267.73	222.89
Add : Balance Brought forward from the previous year	580.48	350.58
Balance carried to the next year	848.22	580.48

Total Revenue has risen by 4.7%. Profit after tax has risen by approximately 21.78%. Though the revenue of the Company has increased by a small percentage but due to effective management and cost of materials declining the profits have grown.

b) Disclosure of Change in Nature of Business:

The Company is engaged in Chemicals. There is no change in nature of Company Business.

c) Details of Directors / Key Managerial Personnel Appointed / Resigned:

During the year under the review, Mr. Parag Manubhai Shah was appointed as an Additional Director with effect from 27th June, 2020. The appointment of Mr. Parag Manubhai Shah as a Director was approved by the shareholders in the annual general meeting of the Company held on 29th September, 2020.

Mrs. Neetu Jalan was appointed as an Additional Director by the Board of Directors with effect from 12th February, 2021.

During the year under the review, no Director or Key Managerial Personnel have resigned.

Further pursuant to provision of Section 149 (10) of the Companies Act, 2013 none of the independent director(s) have completed term of five years and therefore no independent director(s) are eligible for reappointment of second term.

d) Details of Subsidiary Companies / Joint Ventures / Associate Companies:

The Company has s no subsidiary companies / joint ventures / associate companies either at the beginning of the year or at the end of year. However during the year under review, the Company has incorporated 1 wholly owned subsidiary Company namely Arvee Sepeciality Chemicals Private Limited (later name changed to Arvee Speciality Chemicals Private Limited) and the entire investment in wholly

owned subsidiary Company was sold off during the year.

e) Details regarding Deposit covered under Chapter V of the Companies Act, 2013.

The Company has not invited any deposit other than the exempted deposit as prescribed under the provision of the Companies Act, 2013 and the rules framed there under, as amended from time to time. Hence there are no particulars to report about the deposit falling under Rule 8 (5) (v) and (VI) of Companies (Accounts) Rules, 2014.

f) Details of Deposit which are not in compliance with requirements of Chapter V of the Act.

Not Applicable

g) Details of Significant and Material Orders passed by Regulators or Courts or Tribunals.

There are no material changes and commitments, if any, affecting the financial position of the Company between the financial years end of the Company and date of the report.

h) Internal financial Controls:

The Company has identified and documented all key internal financial controls, which impact the financial statements. The financial controls are tested for operating effectiveness through ongoing monitoring and review process of the management and independently by the Internal Auditors. In our view the Internal Financial Controls, affecting the financial statements are adequate and are operating effectively.

Extract of Annual Return:

Extract of Annual return pursuant to Section 92 of the Companies Act, 2013 for the year ended on 31st March, 2021 is available on the website of the Company i.e.

www.arveelabs.com

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-harassment policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee are set up at shop floor level to redress complaints received regularly and are monitored by women line supervisors who directly report to the Chairman. All employees (permanent, contractual, temporary, trainees) are covered under the policy. There was no complaint received from any employee during the financial year 2020-21 and hence no complaint is outstanding as on 31.03.2021 for redressal.

Particulars of Employees:

The Particulars of Employees required to be given pursuant to Section 197 of the Companies Act 2013 is provided in **Annexure VII**.

Material Changes and Commitments & Changes, if any affecting the financial Position between financial year end of the Company and date of Report:

There are no material changes and commitments, if any, affecting the financial position of the Company between the financial years end of the Company and date of the report.

Non Disqualification of Directors:

A Certificate obtained from Practicing Company Secretary regarding non disqualification of Directors of the Company is annexed and marked as **Annexure VIII**.

Acknowledgement

Your Directors express their gratitude for the continued support, co-operation, and assistance received by the Company from various Central and State Government Department, Bankers and valued customers of the company.

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**CHAIRMAN CUM MANAGING DIRECTOR
Shalin Sudharkarbhair Patel
(DIN: 01779902)**

ANNEXURE I

This Nomination and Remuneration Policy is being formulated in compliance with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto and Listing Agreement, as amended from time to time. This policy on Nomination and Remuneration of Directors, Key Managerial Personnel and Senior Management has been formulated by the Nomination and Remuneration Committee (NRC or the Committee) and has been approved by the Board of Directors.

CONSTITUTION OF THE COMMITTEE

The Board of Directors of the Company (Board) constituted the committee to be known as the Nomination and Remuneration Committee consisting of three non-executive directors out of which two shall be the Independent Directors. The Chairman of the Committee shall be an Independent Director.

OBJECTIVE AND PURPOSE OF THE POLICY

The objective of the policy is to ensure that

- The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors of the quality required to run the company successfully;
- Relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
- Remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals.

ROLE OF THE COMMITTEE:

The role of the NRC will be the following:

- To formulate criteria for determining qualifications, positive attributes and independence of a Director.
- To formulate criteria for evaluation of Independent Directors and the Board.
- To identify persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down in this policy.
- To carry out evaluation of Director's performance.
- To recommend to the Board the appointment and removal of Directors and Senior Management.
- To recommend to the Board policy relating to remuneration for Directors, Key Managerial Personnel and Senior Management.
- To devise a policy on Board diversity, composition, size.
- Succession planning for replacing Key Executives and overseeing.

- To carry out any other function as is mandated by the Board from time to time and/or enforced by any statutory notification, amendment or modification, as may be applicable.
- To perform such other functions as may be necessary or appropriate for the performance of its duties.

APPOINTMENT AND REMOVAL OF DIRECTOR, KMP AND SENIOR MANAGEMENT

The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and recommend his/her appointment, as per Company's Policy.

A person should possess adequate qualification, expertise and experience for the position he/she is considered for appointment. The Committee has authority to decide whether qualification, expertise and experience possessed by a person is sufficient/satisfactory for the position.

The Company shall not appoint or continue the employment of any person as Whole-time Director who has attained the age of seventy years. Provided that the term of the person holding this position may be extended beyond the age of seventy years with the approval of shareholders by passing a special resolution.

TERM/TENURE

Managing Director/Whole Time Director

The Company shall appoint or re-appoint any person as Executive Chairman, Managing Director or Executive Director for a term not exceeding five years at a time. No re-appointment shall be made earlier than one year before the expiry of term.

Independent Director

An Independent Director shall hold office for a term up to five consecutive years on the Board of the Company and will be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in the Board's report. No Independent Director shall hold office for more than two consecutive terms of up to maximum of 5 years each, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director.

Provided that an Independent Director shall not, during the said period of three years, be appointed in or be associated with the Company in any other capacity, either directly or indirectly. At the time of appointment of Independent Director it should be ensured that number of Boards on which such Independent Director serves is restricted to seven listed companies as an Independent Director and three listed companies as an Independent Director in case such person is serving as a Whole-time Director of a listed company or such other number as may be prescribed under the Act.

Evaluation

The Committee shall carry out evaluation of performance of Director, KMP and Senior Management Personnel yearly or at such intervals as may be considered necessary.

REMOVAL

The Committee may recommend with reasons recorded in writing, removal of a Director, KMP or Senior Management Personnel subject to the provisions and compliance of the Companies Act, 2013, rules and regulations and the policy of the Company.

RETIREMENT

The Director, KMP and Senior Management Personnel shall retire as per the applicable provisions of the Act and the prevailing policy of the Company. The Board will have the discretion to retain the Director, KMP, Senior Management Personnel in the same position/ remuneration or otherwise even after attaining the retirement age, for the benefit of the Company.

POLICY FOR REMUNERATION TO DIRECTORS/KMP/ SENIOR MANAGEMENT PERSONNEL

Remuneration to Managing Director/Whole Time Director

The Remuneration/Commission etc. to be paid to Managing Director/Whole-time Directors, etc. shall be governed as per provisions of the Companies Act, 2013 and rules made there under or any other enactment for the time being in force and the approvals obtained from the Members of the Company. The Nomination and Remuneration Committee shall make such recommendations to the Board of Directors, assist may consider appropriate with regard to remuneration to Managing Director/Whole-time Directors.

Remuneration to Non-Executive /Independent Director

The Non-Executive/Independent Directors may receive sitting fees and such other remuneration as permissible under the provisions of Companies Act, 2013. The amount of sitting fees shall be such as may be recommended by the Nomination and Remuneration Committee and approved by the Board of Directors.

All the remuneration of the Non-Executive/Independent Directors (excluding remuneration for attending meetings as prescribed under Section 197(5) of the Companies Act, 2013) shall be subject to ceiling/ limits as provided under Companies Act, 2013 and rules made there under or any other enactment for the time being in force. The amount of such remuneration shall be such as may be recommended by the Nomination and Remuneration Committee and approved by the Board of Directors or shareholders, as the case may be.

An Independent Director shall not be eligible to get Stock Options and also shall not be eligible to participate in any share based payment schemes of the Company. Any remuneration paid to Non-Executive/Independent Directors for services rendered which are of professional in nature shall not be considered as part of the remuneration for the purposes of clause (b) above if the following conditions are satisfied:

(i) The Services are rendered by such Director in his capacity as the Professional; and (ii) In the opinion of the Committee, the director possesses the requisite qualification for the practice of that profession.

Remuneration to Key Managerial Personnel and Senior Management

The remuneration to Key Managerial Personnel and Senior Management shall consist of fixed pay and incentive any, in compliance with the provisions of the Companies Act, 2013 and in accordance with the Company's Policy.

The Committee for the purpose of administering the Employee Stock Option/Purchase Schemes, shall determine the stock options and other share based payments to be made to Key Managerial Personnel and Senior Management.

The Fixed pay shall include monthly remuneration, employer's contribution to Provident Fund, contribution to pension fund, pension schemes, etc. as decided from time to time. The Incentive pay shall be decided based on the balance between performance of the Company and performance of the Key Managerial Personnel and Senior Management, to be decided annually or at such intervals as may be considered appropriate.

IMPLEMENTATION

The Committee may issue guidelines, procedures, formats, reporting mechanism and manuals in supplement and for better implementation of this policy as considered appropriate. The Committee may Delegate any of its powers to one or more of its members.

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**CHAIRMAN CUM MANAGING DIRECTOR
Shalin Sudharkarbhair Patel
(DIN: 01779902)**

Annexure II

SECRETARIAL AUDIT REPORT

FORM NO. MR-3

FOR THE FINANCIAL YEAR ENDED ON MARCH 31, 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

**To,
The Members,
Arvee Laboratories (India) Limited**

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **ARVEE LABORATORIES (INDIA) LIMITED** (hereinafter called 'the Company'). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the Financial Year ended on March 31, 2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2021 according to the provisions of:

- (i) The Companies Act, 2013 ('the Act') and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

- (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
- (vi) Based on the representation received from the management, we hereby state Other laws applicable specifically to the Company, namely:-
- a) Income Tax Act, 1961
 - b) Goods and Service Tax Act, 2017
 - c) Employees Provident Fund Act
 - d) Employees State Insurance Act, 1948
 - e) Indian Contract Act, 1872
 - f) Negotiable Instruments Act, 1881
 - g) Payment of Gratuity Act, 1972
 - h) Payment of Bonus Act, 1965
 - i) The Indian Contract Act, 1872
 - j) Foreign Trade (Development And Regulation) Act, 1992
 - k) Environment (Protection) Act, 1986
 - l) The Air (Prevention And Control Of Pollution) Act, 1981
 - m) The Water (Prevention And Control Of Pollution) Act, 1974
 - n) Hazardous Wastes (Management And Handling) Rules, 1989
 - o) Factories Act, 1948
 - p) Minimum Wages Act, 1948
 - q) Child Labour (Prohibition And Regulation) Act, 1986
 - r) Industrial Disputes Act, 1947
 - s) Workmen's Compensation Act 1923
 - t) The Sexual Harassment Of Women At Workplace (Prevention, Prohibition And Redressal) Act, 2013
 - u) Customs Act, 1962

I have also examined compliance with the applicable clauses of the Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned hereinabove.

During the Period under review, provisions of the following Acts, Rules, Regulations, Guidelines, Standards, etc. were not applicable to the Company:

- (i) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
- (ii) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; - **NOT APPLICABLE**
- (iii) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; - **NOT APPLICABLE**
- (iv) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; - **NOT APPLICABLE** and
- (v) The Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998; - **NOT APPLICABLE**

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the Minutes of the meetings duly recorded and signed by the Chairperson the decisions of the Board were unanimously and no dissenting views have been recorded.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**For Jalan Alkesh & Associates
Company Secretaries**

Sd/-

**Date : 17/07/2021
Place : Ahmedabad**

**Alkesh Jalan
FCS: 10620 CP NO: 4580
UDIN: F010620C000477152**

Note: This report is to be read with our letter of even date which is annexed as 'ANNEXURE-A' and forms an integral part of this report.

ANNEXURE-A

**To,
The Members of
Arvee Laboratories (India) Limited**

Our report of even date is to be read along with this letter:

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. Where ever required, we have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For Jalan Alkesh & Associates
Company Secretaries**

Sd/-

**Date : 17/07/2021
Place : Ahmedabad**

**Alkesh Jalan
FCS: 10620 CP NO: 4580
UDIN: F010620C000477152**

Annexure III

SECRETARIAL COMPLIANCE REPORT OF **ARVEE LABORATORIES (INDIA) LIMITED FOR THE YEAR ENDED ON 31ST MARCH, 2021**

I, Alkesh Jalan, Proprietor of Jalan Alkesh & Associates have examined:

- (a) all the documents and records made available to us and explanation provided by **Arvee Laboratories (India) Limited**,
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification, for the year ended **31st March, 2021** ("Review Period") in respect of compliance with the provisions of :
 - (i) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
 - (ii) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; - **NOT APPLICABLE**
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; - **NOT APPLICABLE**
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; - **NOT APPLICABLE**
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013; - **NOT APPLICABLE**
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) other regulations as applicable) and circulars/ guidelines issued thereunder; and based on the above examination, I hereby report that, during the Review Period:

(i) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:-

Sr. No.	Compliance Requirement (Regulations / Circulars / guidelines including specific clause)	Deviations	Observations / Remarks of the Practicing Company Secretary
To the Best of our knowledge the Company has complied with the applicable regulations, circulars, and guidelines during the year under the review. Our reporting is restricted to the compliances falling under financial year 2020 – 2021			

- (ii) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my/our examination of those records.
- (iii) The following are the details of actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

Sr. No.	Action taken	Details of violation	Details of action taken e.g. fines, warning letter, debarment	Observations / Remarks of the Practicing Company Secretary, if any.
Based on the declaration received from the Directors, no action was taken by SEBI or Stock Exchange against the Company. The Company do not have any material subsidiary during the year. Further we hereby state that no action was taken on the promoters or directors by SEBI or Stock Exchange. Our reporting is restricted to the compliances falling under financial year 2020 – 2021				

- (iv) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations of the Practicing Company Secretary in previous reports	Observations made in the Secretarial Compliance Report for year ended on	Actions taken by the listed entity, if any.	Comments on the Practicing Company Secretary on the actions taken by the listed entity
Not Applicable.				

**For Jalan Alkesh & Associates
Company Secretaries**

Sd/-

**Date : 17/07/2021
Place : Ahmedabad**

**Alkesh Jalan
FCS: 10620 CP NO: 4580
UDIN: F010620C000477152**

ANNEXURE IV

CORPORATE GOVERNANCE

Company Philosophy on Corporate Governance

Arvee Laboratories (India) Limited (hereinafter referred as “Arvee” or “the Company”) believes in the highest level of accountability towards its stakeholders and actively promotes fair, transparent and ethical Corporate Governance practices. The Company is committed to maintain the highest standards of Corporate Governance and continue to improve the same time to time.

Corporate governance broadly refers to the mechanisms, processes and relations by which company is controlled and directed. Corporate governance includes the processes through which company’s’ objectives are set and pursued in the context of the social, regulatory and market environment. Governance mechanisms include monitoring the actions, policies, practices, and decisions of companies, their agents, and affected stakeholders.

The Company has adopted the best practices of Corporate Governance over a period of time as per the provisions of SEBI (LODR) Regulations, 2015 and the Companies Act, 2013.

Board of directors

The Company’s policy is to have an appropriate blend of executive, independent and non-independent directors to maintain independence of the Board and to separate the Board functions of governance from that of management.

Composition

As per regulation 17(1) (b) of the SEBI Listing Regulations, where the Chairman is non-executive or a promoter, at least one half of the Board of a Company should consist of independent directors. According to the following table this provision is met at Arvee Laboratories (India) Limited.

As on 31 March 2021, the Board consisted of 6 directors, of whom two are executive (including the managing director and Whole time Director), four are non-executive as well as independent (including 1 women independent director) The Board has no institutional nominee director.

10 Board Meetings were held during the year. The dates of Board meetings and attendance of Director at each Board meeting is detailed in the Directors Report.

Name of the Director and Director Identification Number	Category	Relationship with other Directors	Number of Shares held as at 31st March, 2021	Number of Board Meetings attended	Attendance at last Annual General Meeting
Shalin Sudhakarbhai Patel (DIN : 01779902)	Managing Director [Promoter and Executive]	Nil	33,80,000	10/10	Yes
Shalin Bharatbhai Chokshi (DIN : 00191903)	Whole time Director [Promoter and Executive]	Nil	13,38,000	10/10	Yes
Vishal Nitin Mehta (DIN : 07977497)	Independent and Non-Executive	Nil	0	10/10	Yes
Chandrakala Ashok Bhatt (DIN : 07977517)	Independent and Non-Executive	Nil	0	10/10	No
Paragbhai Manubhai Shah (DIN : 08773974)	Independent and Non-Executive	Nil	0	9/10	Yes
Neetu Rishi Jalan (DIN : 08719470)	Independent and Non-Executive	Nil	0	1/10	Not Applicable

No convertible instrument is issued by the Company and therefore no convertible instrument is held by any Director.

Board Diversity

The Board comprises adequate number of members with diverse experience and skills, such that it best serves the governance and strategic needs of the Company. The directors are persons of eminence in areas such as business, industry, finance, law, administration, economics etc. and bring with them experience and skills which add value to the performance of the Board. The directors are selected purely

on the basis of merit with no discrimination on race, colour, religion, gender or nationality.

A brief profile of the directors is available on the website of the Company at [www.http://arveelabs.com/doc/BOARD_OF_DIRECTORS.pdf](http://arveelabs.com/doc/BOARD_OF_DIRECTORS.pdf)

Opinion of the Board

The Board confirms that, in its opinion, the independent directors on the Board fulfil the conditions specified in the SEBI Listing Regulations and the Act and are independent of the management.

Information supplied to the Board

In advance of each meeting, the Board is presented with relevant information on various matters related to the working of the Company, especially such that require deliberation at the highest level. Presentations are also made to the Board by different functional heads on important matters from time to time. Directors have separate and independent access to the officers of the Company. In addition to such items as required to be placed before the Board for its noting and/or approval, information is provided on various other significant items as well.

In terms of quality and importance, the information supplied by the management to the Board of the Company is far ahead of the list mandated under regulation 17(7) read with Part A of Schedule II to the SEBI Listing Regulations.

The independent directors of the Company at their meeting held on 24th August, 2020 have expressed satisfaction on the quality, quantity and timeliness of flow of information between the Company's management and the Board and have confirmed that these significantly aid the Board to effectively and reasonably perform its duties.

Pursuant to various regulatory requirements and in compliance with applicable laws and keeping in view the business requirements, the Board is, inter alia, apprised on the following:

- Business plans, forecast and strategic initiatives.
- Capital expenditure and updates.
- Internal financial controls.
- Succession planning and organization structure.
- Details of incidence of frauds and corrective action taken thereon.
- Performance of subsidiaries.
- Status of compliances with Companies Act, 2013, SEBI regulations and shareholder related matters.
- Various policies framed by Company from time to time.
- Risk management system, risk management policy and strategy followed.
- Compliance with corporate governance standards.
- Minutes of Board committees.
- Compliance with fair practices code.

Directors and officers liability insurance (D&O policy)

The Company is not required to obtain Directors and Officers Liability Insurance

Policy.

Orderly succession to Board and senior management

Pursuant to regulation 17(4) of the SEBI Listing Regulations, the framework of succession planning for the Board and senior management is placed before the Board for its review. During the year under review, the Board of the Company satisfied itself that plans are in place for orderly succession of such appointments.

Directorship and Membership of Board Committees as on 31st March, 2021

Name of the Director	Directorship in other Listed Entities	Directorship in Unlisted Public Limited Companies	Committee positions in listed and unlisted public limited companies
Shalin Sudhakarbai Patel	1	0	
Shalin Bharatbhai Chokshi	0	0	0
Vishal Nitin Mehta	0	0	0
Chandrakala Ashok Bhatt	0	0	0
Paragbhai Manubhai Shah	0	0	0
Neetu Rishi Jalan	0	1	1 [Member of Audit Committee]

Notes: None of the directors holds office as a director, including as alternate director, in more than 20 companies at the same time. None has directorships in more than 10 public companies. For reckoning the limit of public companies, directorships of private companies that are either holding or subsidiary company of a public company are included and directorships in dormant companies are excluded.

For the purpose of considering the limit of the committees in which a director can serve, all public limited companies, whether listed or not, have been included and all other companies including private limited companies, foreign companies and companies under section 8 of the Act, have been excluded. Only audit committees and stakeholders' relationship committees are considered for the purpose of reckoning committee positions.

As per declarations received, none of the directors serves as an independent director in more than seven equity listed companies or in more than three equity listed companies in case he or she is a whole-time director in any listed company.

None of the directors was a member in more than 10 committees, nor a chairperson in more than five committees across all companies in which he/she was a director. Notwithstanding the number of directorships, as has been highlighted herein, the outstanding attendance record and participation of the directors in Board and

committee meetings indicate their commitment and ability to devote adequate time to their responsibilities as the Company's fiduciaries.

Certificate from practicing Company Secretary

The Company has received a certificate from Alkesh Jalan, practicing Company Secretary to the effect that none of the directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as directors of the Company by the Ministry of Corporate Affairs or any other statutory authority. This certificate forms part of this report.

Review of legal compliance reports

The Board periodically reviews compliance reports with respect to the various laws applicable to the Company, as prepared and placed before it by the management.

Code of conduct

Regulation 17(5) of the SEBI Listing Regulations, requires listed companies to lay down a code of conduct for its directors and senior management, incorporating duties of directors as laid down in the Act. The same is displayed on the website of the Company namely http://arveelabs.com/doc/CODE_OF_CONDUCT.pdf

All directors and senior management personnel have affirmed compliance with the code for FY2021.

A declaration to this effect signed by the Managing Director is given in this annual report.

Maximum tenure of independent directors

The maximum tenure of independent directors is in accordance with the Act and regulation 25(2) of the SEBI Listing Regulations.

Formal letter of appointment to independent directors

The Company issues a formal letter of appointment to independent directors in the manner as provided in the Act. As per regulation 46(2) of the SEBI Listing Regulations, the terms and conditions of appointment of independent directors are available on the Company's website namely http://arveelabs.com/doc/TERMS_AND_CONDITIONS_FOR_APPOINTMENT_OF_INDEPENDENT_DIRECTOR.pdf

Familiarization Programme

With a view to familiarizing the independent directors with the Company's operations, as required under regulation 25(7) of the SEBI Listing Regulations, the Company has held various familiarization programmes for the independent directors throughout the year on an ongoing and continuous basis.

The details of familiarization programmes are placed on website of the Company namely

http://arveelabs.com/doc/FAMILIARIZATION_PROGRAMMES_IMPARTED_TO_INDEPENDENT_DIRECTORS.pdf

Whistle Blower Policy/Vigil mechanism

Pursuant to section 177(9) of the Act, regulation 22 of the SEBI Listing Regulations and SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Board of Directors have adopted the Whistle Blower Policy.

The Whistle Blower Policy/Vigil mechanism provides a mechanism for the director/employee to report without fear of victimization, any unethical behaviour, suspected or actual fraud, violation of the Code of Conduct and instances of leak of Unpublished Price Sensitive Information, which are detrimental to the organisation's interest. The mechanism protects whistle blower from any kind of discrimination, harassment, victimization or any other unfair employment practice. The Company affirms that no employee has been denied access to the Audit Committee.

The directors in all cases and employees in appropriate cases will have direct access to the Chairman of the Audit Committee. The said Policy is placed on the Company's website http://arveelabs.com/doc/VIGIL_MECHANISM.pdf

Dividend Distribution Policy

Pursuant to Regulation 43A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) the Company has adopted dividend distribution policy. The details of distribution policy is available on the website of the Company namely http://arveelabs.com/doc/Dividend_Policy.pdf

Material Subsidiary Company Policy

As at 31st March 2021 the Company has no subsidiary. Further during the year under review there was no material subsidiary Company as defined under regulation 16(1)(c) of the SEBI Listing Regulations.

The policy on 'material subsidiaries' in terms of regulation 16(1) (c) of the SEBI Listing Regulations is available on website of Company namely http://arveelabs.com/doc/OTHER_POLICIES.pdf

The details of subsidiary Company incorporated and disposed of during the year is disclosed in Directors Report.

Provisions to the extent applicable as required under regulation 24 of the SEBI Listing Regulations with reference to subsidiary companies were duly complied with.

During the year under review, the Audit Committee reviewed the financial statements (in particular, the investments made) of its unlisted subsidiary companies, to the extent applicable. Minutes of the Board meetings of the subsidiary companies as well as a statement of significant transactions and arrangements entered into by the subsidiaries, as applicable, were regularly placed

before the Board of the Company.

Related Party Transactions

All related party transactions (RPTs) which were entered into by the Company during the year under review, were on arms' length basis and in the ordinary course of business and did not attract provisions of section 188 of the Act and were also not material RPTs as per regulation 23 of the SEBI Listing Regulations.

All RPTs during the year 2020-21 were entered into with the approval of the Audit Committee pursuant to provisions of Act and the SEBI Listing Regulations. The details of such transactions were placed before the Audit Committee for noting/review, on a quarterly basis.

A statement showing the disclosure of transactions with related parties as required under Indian Accounting Standard 24 (Ind AS 24) is set out separately in this Annual Report. There were no material transactions entered into with related parties, during the year under review, which may have had any potential conflict with the interests of the Company. The Policy on materiality of RPTs stipulating the threshold limits and also on dealing with RPTs pursuant to SEBI Listing Regulations has been placed on the Company's website http://arveelabs.com/doc/RELATED_PARTY_TRANSACTION_POLICY.pdf

Disclosures

Suitable disclosures have been made in the financial statements, together with the Management's explanation in the event of any treatment being different from that prescribed in the Ind AS.

Core Skill/Expertise/Competencies

As stipulated under Schedule V of the SEBI Listing Regulations, core skills/expertise/competencies, as required in the context of the business and sector for it to function effectively and those actually available with the Board have been identified by the Board of Directors.

As a green initiative, the Chart/Matrix of such core skills/expertise/competence along with the names of directors who possess such skills is as under:

Name of the Director	Skills / Competence of Directors
Shalin Patel	Production, Legal, Administrative, Finance, Marketing, Commercial aspect
Shalin Chokshi	Production, Marketing, Quality, Supply Chain Management, Administration
Neetu Jalan	Administrative
Vishal Nitin Mehta	Finance, Administration, Legal and Commercial
Chandrakala Ashok Bhatt (up to 17.7.2021)	Finance, Administration, Legal and Commercial
Parag Manubhai Shah	Finance, Administration, Legal and Commercial

Committees

a. Audit Committee

The Audit Committee was originally constituted as pursuant to a resolution passed by our Board at its meeting held on December 04, 2017 and last re-constituted pursuant to a resolution passed by our Board at its meeting held on June 27, 2020. The scope and functions of the Audit Committee are in accordance with section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI Listing Regulations.

The Board reviews the working of the Committee from time to time to bring about greater effectiveness in order to comply with the various requirements under the Act and the SEBI Listing Regulations.

In compliance with the provisions of the Act and the SEBI Listing Regulations, all the members are independent, non-executive directors and are financially literate and have accounting or related financial management expertise.

The detailed terms of reference of Audit Committee have been placed on the Company's website <http://arveelabs.com/doc/COMMITTEES.pdf>

The composition of audit committee is as under:

Name of the Director	Designation
Vishal Nitin Mehta	Independent Director
Chandrakala Ashok Bhatt	Independent Director
Shalin Sudhakarbhair Patel	Managing Director

Vishal Nitin Mehta acts as a Chairman of the Committee. The Company Secretary of the Company acts as the Secretary to the Audit committee. All the recommendations of the audit committee have been accepted. The audit Committee met 4 times on following dates:

Date of Audit Committee Meeting	No of Directors entitled to attend the meeting	No. of Directors attending the meeting	Attended by Director
29 th June, 2020	3	3	1. Mr. Vishal Nitin Mehta 2. Mrs. Chandrakala Ashok Bhatt 3. Mr. Shalin Patel
24 th August, 2020	3	3	1. Mr. Vishal Nitin Mehta 2. Mrs. Chandrakala Ashok Bhatt 3. Mr. Shalin Patel
5 th November,	3	3	1. Mr. Vishal Nitin Mehta

2020			2. Mrs. Chandrakala Ashok Bhatt 3. Mr. Shalin Patel
8 th February, 2021	3	3	1. Mr. Vishal Nitin Mehta 2. Mrs. Chandrakala Ashok Bhatt 3. Mr. Shalin Patel

All the recommendations of audit committee were accepted by the Board. Mr. Vishal Nitin Mehta, Chairman of audit committee was present at the annual general meeting for the year 2020 to answer shareholders queries.

b. Nomination and Remuneration Committee

The Nomination and Remuneration Committee was constituted pursuant to a Board meeting of our held on December 04, 2017 and last re-constituted pursuant to a resolution passed by our Board at its meeting held on June 27, 2020. The scope and functions of the Nomination and Remuneration Committee are in accordance with section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI Listing Regulations.

The detailed terms of reference of Nomination and Remuneration Committee have been placed on the Company's website namely <http://arveelabs.com/doc/COMMITTEES.pdf>

The role of Nomination and Remuneration Committee is as under:

1. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of Directors a policy relating to, the remuneration of the directors, Key Managerial Personnel and other employees.
2. Formulation of criteria for evaluation of performance of Independent Directors and the Board of Directors.
3. Devising a policy on diversity of Board of Directors.
4. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal.
5. Whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors.
6. Such other matters as may from time to time be required by any statutory, contractual or other regulatory requirements to be attended to by such committee.

The composition of Nomination and Remuneration Committee is as under

Name of the Director	Status in Stakeholders Relationship Committee
Mr. Vishal Nitin Mehta	Chairman of Committee
Parag Manubhai Shah	Member
Chandrakala Ashok Bhatt	Member

The Company Secretary acts as a secretary of the Committee.

Date of Meeting of Nomination and Remuneration Committee	No. of Directors entitled to attend the meeting	No. of Directors attended the meeting
24 th August, 2020	3	3
5 th November, 2020	3	3

All the recommendation of Nomination and Remuneration Committee were accepted by the Board.

Stakeholders Committee

The Stakeholders' Relationship Committee was constituted by our Board at their meeting held on December 04, 2017 and last re-constituted pursuant to a resolution passed by our Board at its meeting held on June 27, 2020. The scope and functions of the Stakeholders' Relationship Committee are in accordance with section 178 of the Companies Act, 2013 and Regulation 20 of the SEBI Listing Regulations.

The terms of reference of the Stakeholders Relationship Committee include the following:

1. Redressal of shareholders'/investors' complaints.
2. Reviewing on a periodic basis the approval of transfer or transmission of shares, debentures or any other securities made by the Registrar and Share Transfer Agent;
3. Issue of duplicate certificates and new certificates on split/consolidation/renewal.
4. Non-receipt of declared dividends, balance sheets of the Company.
5. Carrying out any other function as prescribed under the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The composition of Stakeholders Relationship Committee is as under:

Name of the Director	Status in Stakeholders Relationship Committee
-----------------------------	--

Vishal Nitin Mehta	Chairman of the Committee
Shalin Sudhakarbhai Patel	Member
Parag Manubhai Shah	Member

Two Meetings of Stakeholders Committee was held during the year namely on 24.08.2020 and 5.11.2020. The Meetings were attended by all the members of the Committee.

The Company Secretary acts as a secretary of the Committee. All recommendations of Stakeholders Committee have been accepted by the Board.

Mrs. Raina Singh Chauhan, Company Secretary is the compliance officer. No complaints was received during the year and no complaints were pending at the end of year.

Risk Management Committee: Not Applicable.

Independent Directors' Meeting

In compliance with Schedule IV to the Companies Act, 2013 and regulation 25(3) of the SEBI Listing Regulations, the independent directors held their separate meeting on 24th August, 2020, without the attendance of non-independent directors and members of the management, to inter alia discuss the following:

- i) Review of Vigil Mechanism;
- ii) Review the performance of non-independent directors and the Board as a whole;
- iii) Review the performance of the Chairperson of the Company, taking into account the views of executive directors and non-executive directors;
- iv) Assess the quality, quantity and timeliness of flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform their duties;
- v) Noting and review of Informal meeting with senior management personnel.

All independent directors were present at the meeting. The independent directors present elected Mr. Vishal Nitin Mehta as Chairman for the meeting, deliberated on the above and expressed their satisfaction on each of the matters.

Pecuniary relationship/transaction with non-executive directors

During the year under review, there was no pecuniary relationship/transaction with any non-executive director of the Company.

Payments to Non-Executive Directors:

No payment was made to any Non-Executive Directors.

Executive directors

During the year under review, the Company paid remuneration to Shalin Patel, Executive Chairman cum Managing Director of Rs. 36,72,946/- and Shalin Chokshi, Whole Time Director of the Company of Rs. 36,72,946/- .

Disclosure of material transactions

Pursuant to regulation 26(5) of the SEBI Listing Regulations, the Senior Management has made periodical disclosures to the Board relating to all material financial and commercial transactions, where they had (or were deemed to have had) personal interest that might have been in potential conflict with the interest of the Company. The same was Nil.

Shareholding of directors

Information on shares held by directors in the Company as on 31 March 2021 is as under :

Sl. no		Shareholding at the beginning of the year		Shareholding at the end of the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Shalin Sudhakarbhair Patel	1690000	30.671	3380000	30.671
2	Shalin Bharatbhair Chokshi	669000	12.141	1338000	12.141
3	Chandrakala Ashok Bhatt	0	0	0	0
4	Parag Manubhai Shah (w.e.f. 27/06/2020)	0	0	0	0
5	Neetu Jalan (w.e.f 12/2/2021)	0	0	0	0
6	Vishal Nitin Mehta	0	0	0	0

Compliances regarding insider trading

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company had a Board-approved Code of Conduct to regulate, monitor and report trading by insiders ('Code of Conduct') and a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information ('Code of Fair Disclosure'). The Code of conduct is available on website of the company namely http://arveelabs.com/doc/DISCLOSURE_OF_UNPUBLISHED_PRICE_SENSITIVE_INFORMATION.pdf

Means of Communication

The Company has its own website, www.arveelabs.com which contains all important public domain information including presentations, if any, made to the media, analysts and institutional investors.

The website contains information as prescribed under the Act and SEBI Listing Regulations including details of the corporate contact persons and share transfer agent of the Company, shareholding pattern etc.

Section 20 and 136 of the Act, read with Companies (Accounts) Rules, 2014 permit companies to service delivery of documents electronically on the registered members'/shareholders' email addresses. The Company, during the year under review, sent documents, such as notice calling the general meeting, audited financial statements, directors' report, auditors' report etc. in electronic form at the email addresses provided by the shareholders. Shareholders desiring to receive the said documents in physical form continued to get the same in physical form, upon request, during the year under review.

All financial and other vital official news releases and documents under the SEBI Listing Regulations are also communicated to the concerned stock exchanges, besides being placed on the Company's website www.arveelabs.com

Information on general body meetings held during the last three years and details of special resolution(s) passed

Details of AGM	Date and Time of Annual General Meeting and Venue	Details of Special Resolution(s) passed, if any.
7 TH AGM	Saturday, 18 TH August, 2018 at 10.00 a.m. at Ahmedabad Management Association, Torrent-AMA Management Centre, Core-AMA Management House, ATIRA Campus, AMA Complex, Dr. V S Marg, Vastrapur, Ahmedabad 380 015	Nil
8 th AGM	Thursday, 8 th August, 2019 at 10.00 a.m. at Ahmedabad Management Association, Torrent-AMA Management Centre, Core-AMA Management House, ATIRA Campus, AMA Complex, Dr. V S Marg, Vastrapur, Ahmedabad 380 015	Nil
9 th AGM	Tuesday, 29 th September,	1. Capitalization of Reserves

	2020 at 11.00 a.m. through Audio Video Conference Mode	for the issue of Bonus Shares in ratio of 1 : 1
--	--	--

Postal Ballot

During the year under review the Company has passed Special resolution through Postal Ballot Process for Migration of Listing/ Trading of Equity Shares of the Company from SME Platform (EMERGE) of National Stock Exchange of India (NSE) to Main Board of NSE. The Company has appointed Jalan Alkesh & Associates, Practicing Company Secretary as Scrutinizer for the same.

The results of the Postal ballot are available on the website of the Company.

Details of capital market non-compliance, if any

There was no non-compliance by the Company of any legal requirements; nor has there been any penalty/stricture imposed on the Company by any stock exchange, SEBI or any statutory authority on any matter related to capital markets during the last three years.

Disclosure under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The disclosure as required under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 is given in the Directors' Report of the Company.

Compliance Certificate

The MD and the CFO have certified to the Board with regard to the financial statements and other matters as required under regulation 17(8) read with Part B of Schedule II to the SEBI Listing Regulations

Annual General Meeting

Friday, 24th September, 2021 at 11:30 a.m. at the Registered Office of the Company situated at 403, Entice, Nr. Jayantilal Park BRTS, Iskcon - Bopal Road, Ambli Ahmedabad, Gujarat - 380058

Book Closure Dates

Saturday, 18th September, 2021 to Friday, 24th September, 2021 (both days inclusive)

Financial Year: April 1 to March 31

Financial Calendar year (2021 – 2022)

Quarterly Results	Schedule
Quarter ended on 30 th June, 2021	17 th July, 2021
Quarter ended on 30 th September, 2021	On or before 14 th November, 2021 (tentative)
Quarter ended on 31 st December, 2021	On or before 14 th February, 2022 (tentative)
Quarter ended on 31 st March, 2022	On or before 30 th May, 2022 (tentative)

Dividend

Not Applicable.

Plant Locations

Survey No. 316, Bhavnagar-Sihor Road Navagam (Kardej), Post Vartej - 364060, Bhavnagar, Gujarat, India

Global depository receipts or American depository receipts or warrants or any convertible instruments, conversion date and likely impact on equity

There are no outstanding Global depository receipts or American depository receipts or warrants or any convertible instruments.

Fund Raising

During the year under review the Company has not made any preferential issue of shares or Qualified Institutional Placement and therefore no fund raising activity was carried out. However the Company has made Bonus issue of Equity Shares in the ratio of 1: 1

Commodity price risk or foreign exchange risk and hedging activities

The Company does not deal in commodities and hence the disclosure pursuant to SEBI Circular dated November 15, 2018 is not required to be given.

Share Transfer System

SEBI amended regulation 40 of SEBI Listing Regulations, 2015, prohibiting transfer of securities (except transmission or transposition of shares) in physical form from 1 April 2019. During FY2021, no shares were transferred in the physical form except for those for whom the transfer deed was lodged prior to 1 April 2019 and were returned due to deficiency in the document and were thus re-lodged post 1 April 2019.

Dematerialization of Shares

100% shares of the Company are in dematerialized form.

Position of Shares as on 31st March, 2021

	Number of Shares	% of Total Issued Capital
NSDL	1104010	10.02
CDSL	9915990	89.98
Physical	0	0
Total	11020000	100

ISIN: INE006Z01016

Corporate Identity Number: L24231GJ2012PLC068778

Stock Code

The Shares of the Company are listed on National Stock Exchange of India (Main Board) Exchange Plaza, 5th Floor Plot No.C-1, G Block Bandra-Kurla Complex Bandra (East), Mumbai 400 051 and Scrip code is ARVEE. The Company has paid listing fees for the year 2020 – 2021.

Distribution of Shareholding

Month	High	Low	NSE High	NSE Low
April, 2020	-	-		
May, 2020	-	-		
June, 2020	39.95	37.60		
July, 2020	-	-		
August, 2020	70.20	41.30		
September, 2020	77	70.05		
October, 2020	79.75	41.50		
November, 2020	-	-		
December, 2020	-	-		
January, 2021	-	-		
February, 2021	-	-		
March, 2021 *	55.50	43.54	12395.8	11939

* Since the Equity Shares of the Company are listed on the Capital Market Segment of National Stock Exchange with effect from 22nd March, 2021 the prices of the Shares prior to the above mentioned period is based on NSE Emerge Platform. Further since the shares have been listed on Capital Market segment with effect from 22nd March, 2021 the comparative indicies are given only for the month of March, 2021.

Distribution of Shareholding according to size

SR NO	SHAREHOLDING OF NOMINAL		NUMBER OF SHAREHOLDERS	% TO TOTAL No. of Holders	SHARES	% TO TOTAL Shares
1	1	500	5	7.0423	1100	0.01
2	501	2000	6	8.4507	12000	0.1089
3	2001	3000	1	1.4085	2900	0.0263
4	3001	4000	42	59.1549	168000	1.5245
5	5001	10000	4	5.6338	32000	0.2904
6	10001	99999999	13	18.3099	10804000	98.0399
TOTAL			71	100.00	11020000	100.00

Distribution of shareholding across categories

Distribution of Shareholding across categories as at 31st March, 2021 is as under:

Category	No. of Shares	% of total Capital
Individuals / Huf of Promoter and Promoter Group	8100000	73.5
Individuals (Public)	2899890	26.32
HUF / Trust / NRI (Public)	20110	0.18
Total	11020000	100

Shareholders' and investors' grievances

The Board of Directors of the Company has a Stakeholders' Relationship Committee to specifically look into and resolve grievances of security-holders on various matters. No complaint is received during the year.

SEBI Complaints Redress System (SCORES)

SEBI administers a centralized web-based complaints redress system (SCORES). It enables investors to lodge and follow up complaints and track the status of redressal online on the website www.scores.gov.in. It also enables the market intermediaries and listed companies to receive the complaints from investors against them, redress such complaints and report redressal. All the activities starting from lodging of a complaint till its disposal are carried online in an automated environment and the status of every complaint can be viewed online at any time. The Company has registered itself on SCORES and endeavors to resolve all investor complaints received through SCORES. There was no unattended or pending investor grievance as on March 31, 2021.

Details of Investor Complaints Received and redressed during the year 2020-21 are as follows:

Opening Balance	Received during the year	Resolved during the year	Closing Balance
-----------------	--------------------------	--------------------------	-----------------

0	0	0	0
---	---	---	---

Investor Education and Protection Fund

No amount was required to be transferred to the Investor Education and Protection Fund.

Unclaimed Shares Suspense Account

As per Regulation 34(3) and 39(4) read with Schedule V of the Listing Regulations, no shares are to be required to be transferred to Unclaimed Shares Suspense Account and consequently the applicable details are nil or not applicable.

Credit Rating

The Company has neither issued any debt instruments nor undertaken any fixed deposit programme or any scheme or proposal involving mobilization of funds, whether in India or abroad.

Share Transfer Agent

The work related to Share Transfer agent of the Company is handled by Bigshare Services Private Limited and accordingly, processing of share transfer/dematerialization/dematerialization and allied activities was outsourced to Bigshare Services Private Limited. All physical transfers (to the extent permitted), transmission, transposition, issue of duplicate share certificate(s), issue of demand drafts in lieu of dividend warrants etc. as well as requests for dematerialisation/rematerialisation are being processed in periodical cycles by Bigshare Services Private Limited. The work related to dematerialisation/rematerialisation is handled by Bigshare Services Private Limited through connectivity with NSDL and CDSL.

Address of Share Transfer Agent

Bigshare Services Private Limited Registered Office : 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400059.

Company Secretary and Compliance Officer

Mrs. Raina Singh Company Secretary
403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad 380058.

Address for Correspondence

Arvee Laboratories (India) Limited

403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad 380058.

Email: compliance@arveelabs.com

www.arveelabs.com

Email id for Investor Grievance: compliance@arveelabs.com

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**CHAIRMAN CUM MANAGING DIRECTOR
Shalin Sudharkarbhay Patel
(DIN: 01779902)**

Annexure V

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Industry Structure and developments

Chemicals industry in India is highly diversified, covering more than 80,000 commercial products. It is broadly classified into Bulk chemicals, Specialty chemicals, Agrochemicals, Petrochemicals, Polymers and Fertilizers. India's proximity to the Middle East, the world's source of petrochemicals feedstock, makes for economies of scale. India is a strong global dye supplier, accounting for approximately 16% of the world production of dyestuff and dye intermediates. The Chemical industry in India provides several raw materials for many industries, including textiles, paper, paints, soap and detergents, pharmaceuticals and agrochemicals. The production of Total Major Chemicals and Petrochemicals in 2020-21 (up to September 2020) was 12,502 thousand MT. CAGR in production of Total Chemicals and Petrochemicals during the period 2015-16 to 2019-20 is 5.74%. Alkali Chemicals accounts for around 71% of the total production of Major Chemicals for the year 2019-20 (up to September 2019).

- The Chemicals and Petrochemicals market is projected to reach \$300 bn by 2025.
- The specialty chemicals constitute 18% of total chemicals and petrochemicals market in India. As of FY19, the total market size is around \$32 bn. The demand for speciality chemicals is expected to grow at 12% CAGR from FY19-22.
- Export of chemicals and chemical products grew at a CAGR of 7.2% between FY16 and FY20.
- Demand of chemical products is expected to grow at approximately 9% p.a. during 2020-25.
- The petrochemical demand is expected to grow at 7.5% CAGR from FY 2019-23.
- The Chemical industry (including fertilizers and pharmaceuticals) in India stands at USD 178 Bn as of 2019 which is expected to reach USD 304 Bn by 2024-25 at an annual growth rate of 9.3%.
- India's Chemical Industry ranks at the 6th position in the world and 4th position in Asia in terms of size.
- Indian chemicals and petrochemicals industry is growing to new heights, looking forward to an investment of INR 8 lakh cr by 2025.
- Indian chemical industry employs more than 2 million people.

Reasons to Invest

The growth drivers of the sector in India include a large domestic and foreign demand for chemicals and petrochemicals. Four Petrochemical Investment Regions (PCPIRs) policies being implemented in Andhra Pradesh, Gujarat, Odisha and Tamil Nadu which is expected to attract investment of around INR 7.63 lakh cr. The value additions in the petrochemicals chain offer immense possibilities and cater to the needs of textiles and clothing, agriculture,

packaging, infrastructure, healthcare, furniture, automobiles, information technology, power, electronics and telecommunication, irrigation, drinking water, construction and a variety of other articles of daily and specialized usage amidst other emerging areas. In recent times, there has been a global shift towards Asia as the world's chemical manufacturing hub. India also offers the availability of a large pool of skilled science professionals. India has several world-class engineering facilities and strong R&D capabilities. The per capita consumption of chemicals is lower in India, compared to western countries, therefore presenting immense scope for setting up export-oriented manufacturing units through new investments. To promote investments in the sector, the government is implementing four Petroleum, Chemical and Petrochemical Investment Regions (PCPIR) in the country. PCPIRs will be clustered providing investors with a transparent and investment-friendly policy and facility regime.

1.4%	11.3%	2.5%
Nation's Gross Value Added	Chemical products exports share	Contribution to global chemical sales

Major Segments of the Indian Chemical Industry

1. Base chemicals: Petrochemicals, man-made fibers, industrial gases, fertilisers, chlor-alkali and other organic and inorganic chemicals.
2. Speciality Chemicals: Dyes and pigments, leather chemicals, construction chemicals, personal care ingredients and other speciality chemicals.
3. Pharmaceuticals: Active Pharmaceutical ingredients (API's) and formulations
4. Agrochemicals: Insecticides, herbicides, fungicides, and other crop protection chemicals.
5. Biotechnology: Bio-pharma, bio-agri, bio-services and bio-industrial products.

Opportunities

Despite the current critical financial and economic hurdles, the expected positive long term economic development and the increasing freight transport volumes constitute an opportunity for the growth and the further development of most of the chemical enterprises. This can be an important contribution to the stabilization of markets and the improvement of customer satisfaction.

Threats

The present economic position serves as a threat to many chemical companies both worldwide and on the regional level. In general labour avoid working in chemical plants. Hence company may have to face labour problem.

OUR STRATEGIES

Expansion of our presence in the domestic markets

Our Company seeks to expand and enhance our presence in our existing business segments by identifying markets where we can provide cost effective, technically advanced products to our clients. Our Company plans to cater to various customers from different geographical locations by following the direct market route for large customers. Our Company would also aim to build-up our sales force which will enable us to effectively market our products.

Meeting Quality Standards and developing customer focus

Our driving force has always been the quality of our products, as the same would enable us for long standing relationship with our customers. Our technical team is equipped with testing facilities to ensure that all our products are thoroughly tested prior to dispatch from our factory. We will continue to strive our quality standards high.

Continue to develop & maintain relationships

We provide services to national as well as international clients. We continue to enjoy the patronage of our clients. We believe that we can leverage our existing relationships, our brand and our technical expertise to grow our client base which would help us in achieving our growth objective.

Reduction in Cost

We continue to monitor and explore all the possible opportunity for reduction in the Cost including manufacturing and administrative cost for maximisation of resources and creation of wealth for shareholders.

Outlook

The outlook for the coming year looks promising for the Chemicals business at this point in time. Demand is showing signs of improvement and with a price advantage due to our best negotiation abilities we are likely to perform well. However, global recession and market condition may have an impact on our business to suffer which in turn can have bearing on profitability. Further with the rise in Delta Variant can be a global cause of concern.

The outlook for the demand of the Products continues to be robust considering the COVID. It is expected that the outlook for the Chemicals sector continues to be bright. In view of the Atmanirbhar Bharat, it is expected that the demand for the Company products will grow manifold.

Risks and Concerns

Your Company had put a risk management framework in place post a comprehensive review of its risk management process. Your Company takes a fresh look at the risk management framework through our Audit Committee at least once in a year. The review involved understanding the existing risk management initiatives and assessment of risks in the businesses as the relative control measures and arriving at the desired counter measures keeping in mind the risk appetite of the organization. The audit Committee has periodically reviewed the risks in the business and recommended appropriate risk mitigating actions. The business of the Company is likely to be affected by various internal and external risks enumerated as under:

- Our success depends largely upon the services of our Promoter, Directors and other key managerial personnel and our ability to attract and retain them.
 - The prices we are able to obtain for the products that we trade depend largely on prevailing market prices.
 - We face intense competition in our businesses, which may limit our growth and prospects.
 - Global economic, political and social conditions may harm our ability to do business, increase our costs and negatively affect our stock price.
 - Global recession and market conditions could cause our business to suffer.
 - Natural calamities and changing weather conditions caused as a result of global warming could have a negative impact on the Indian economy and consequently impact our business and profitability.
 - Tax rates applicable to Our Company may increase and may have an adverse impact on our business.
 - Political instability or changes in the Government could adversely affect economic conditions in India generally and our business in particular.
- As a responsible employer, to ensure occupational safety and employment standards, your Company maintains strict safety and quality control programs to monitor and control these operational risks.

Internal Control System and their adequacy

The Company maintains adequate internal control systems, which provides, among other things, reasonable assurance of recording the transactions of its operations in all material respects and of providing protection against significant misuse or loss of company's assets.

Internal Controls are adequately supported by internal audit and periodical review of by the management. The audit committee meets periodically to review with the management and statutory auditors, financial statements. The Audit Committee also meets with the internal auditors to review adequacy /scope of internal audit function, significant findings and follow up thereon and finding of abnormal nature.

Discussion on financial performance with respect to operational performance

During the year company has reported total income of Rs. 4576.47 lacs as against 4795.98 lacs. Net Profit of the Company during the Current year stand at Rs. 267.73 lacs as against profit of Rs. 229.89 lacs in the previous year.

Material developments in human resources/ Industrial Relations front, including number of people employed

Relations with the employees of the Company at various levels remained harmonial during the year under the review. The Company is making its best efforts to retain and attract talented employees. During the year under the review, the Company has complied with all legislative provisions of labour laws. The number of employees of the company as of 31st March, 2021 was 76.

Other Disclosures

a. Basis of related party transaction:

During the year under the review, related party transactions, if any, are disclosed in the Balance Sheet. Transactions are entered at arm's length.

b. Disclosure of accounting treatments:

The Company has followed all relevant Accounting Standards while preparing the financial Statements.

c. Board Disclosures - Risk Management:

The Company has developed comprehensive risk management policy and same is reviewed by the Audit Committee, which in turn, informs the Board about the risk assessment and minimization procedures. Major risks identified for the Company by the management are Currency fluctuation, Compliance, Regulatory changes, Manufacturing & Supply, Litigation, Information Technology and new capital investments return. The management is however, of the view that none of the above

risks may threaten the existence of the Company as robust Risk mitigation mechanism is put in place to ensure that there is nil or minimum impact on the Company in case any of these risks materialize. Since the risk control frame work is new to Indian Corporate Culture, it is being strengthened on continuous basis using the outside professional help.

d. Proceeds from public issues, right issues, preferential issues etc.:

No issue was made during the year. However there was an issue of Bonus Shares in ratio of 1: 1

Besides above, there was no instance of non-compliance of any matter related to the capital markets during the last three years.

Details of significant changes in key Financial Ratios & Return on Net worth

Pursuant to amendment made in schedule V to the Listing Regulations, details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in Key Financial Ratios and any changes in return on net worth of the Company (on standalone basis) including explanations therefor are given below:

Particulars	FY ended 31st March, 2021	FY ended 31st March, 2020	Changes Between CY and PY	Explanation of changes exceeding 25% in comparison to previous year
(i) Debtors Turnover	6.55%	6.21%	0.33%	Change less than 25% hence reason for change is not required.
(ii) Inventory Turnover	58 Days	53 Days	-5 Days	Since the Company has adopted the policy of having higher inventory the change has occurred
(iii) Interest Coverage Ratio	7.32	4.13	3.19	It is a good sign that there is an increase of 75% in comparison with previous year. It is due to company had prematurely closed its term loan & hence interest burden of company also reduces.
(iv) Current Ratio	1.40	1.44	-0.04	Change less than 25% hence reason for change is not required.

(v) Debt Equity Ratio	0.45	0.24	0.21	Change less than 25% hence reason for change is not required.
(vi) Operating Profit Margin (%)	8.79%	8.91%	-0.12	Change less than 25% hence reason for change is not required.
(vii) Net Profit Margin (%)	5.58%	4.87%	0.71%	Change less than 25% hence reason for change is not required.
(viii) Return on Net worth (%)	24.30%	40.42%	-16.12%	Because of COVID and Lockdown, the Business of the company was adversely impacted

Cautionary Statement

The above Management Discussion and Analysis contains certain forward looking statements within the meaning of applicable security laws and regulations. These pertain to the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties, regarding fluctuations in earnings, our ability to manage growth, competition, economic growth in India, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, government policies and actions with respect to investments, fiscal deficits, regulation etc. In accordance with the Code of Corporate Governance approved by the Securities and Exchange Board of India, shareholders and readers are cautioned that in the case of data and information external to the Company, no representation is made on its accuracy or comprehensiveness though the same are based on sources thought to be reliable. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time on behalf of the Company.

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**CHAIRMAN CUM MANAGING DIRECTOR
Shalin Sudharkarbhair Patel
(DIN: 01779902)**

ANNEXURE VI

CERTIFICATE ON COMPLIANCE WITH THE REGULATIONS OF CORPORATE GOVERNANCE

To
The Shareholders Of
ARVEE LABORATORIES (INDIA) LIMITED

I, Alkesh Jalan, Proprietor of Jalan Alkesh & Associates, Company Secretary in Practice, the Secretarial Auditor of Arvee Laboratories (India) Limited (“the Company”), have examined the compliance of conditions of Corporate Governance by the Company, for the year ended on 31st March 2021, as stipulated in regulations 17 to 27 and clauses (b) to (i) of regulation 46(2) and paras C and D of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments from time to time (the “Listing Regulations”).

MANAGEMENT’S RESPONSIBILITY

The compliance of conditions of Corporate Governance is the responsibility of the Management. This responsibility includes the design, implementation and maintenance of internal control and procedures to ensure compliance with the conditions of the Corporate Governance stipulated in the Listing Regulations.

AUDITORS’ RESPONSIBILITY

- a) My responsibility is limited to examining the procedures and implementation thereof adopted by the Company for ensuring compliance with the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.
- b) I have examined the relevant records and documents maintained by the Company for the purposes of providing reasonable assurance on the compliance with Corporate Governance requirements by the Company.

OPINION

- a) Based on my examination of the relevant records and according to the information and explanations provided to me and the representations provided by the Management, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in regulations 17 to 27 and clauses (b) to (i) of regulation 46(2) and paras C and D of Schedule V of the Listing Regulations during the year ended 31st March 2021.

- b) I state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company Reporting of internal auditor directly to the Audit Committee.

**For, Jalan Alkesh & Associates
Company Secretaries**

Sd/-

**Alkesh Jalan [Proprietor]
FCS: 10620, COP: 4580
UDIN: F010620C000477185
PR: S2002GJ051600**

**Date: 17th July, 2021
Place: Ahmedabad**

ANNEXURE VII

Details under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

A. Ratio of the remuneration of each director to the median remuneration of the employees of the company for the financial year 2020-21 are as follows:

Sr. No.	Directors	Remuneration (Rs in Lakhs)	Median Remuneration (Rs in Lakhs)	Ratio
1.	Shalin Sudhakarbhair Patel	36.72	1.41	26.01 : 1
2.	Shalin Bharatbhair Chokshi	36.72	1.41	26.01 : 1

Other Directors are not paid any remuneration and therefore the comparative ratio is not applicable.

B. The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year 2020-21 are as follows:

Name of the Directors, Chief Financial Officer, Chief Executive Officer, Company Secretary, Manager	Designation	Percentage increase in remuneration
Shalin Sudhakarbhair Patel	Managing Director	196.36
Shalin Bharatbhair Chokshi	Whole Time Director	196.36
Mr. Saurin Gandhi	Chief Financial Officer	16.45
Ms. Raina Singh Chauhan	Company Secretary	0.00

C. The percentage increase in the median remuneration of employees in the financial year 2020-21:

	(Amount in Rs)		
	2020-21	2019-20	Increase (%)
Median Remuneration of Employees	1,41,176	1,36,400	3.50%

D. There were 76 Employees on the payroll of company as on 31st March, 2021.

E. Comparison of average Percentile increase in salary of employees other than the managerial personnel and the percentage increase in the remuneration paid to managerial personnel:

	(Amount in Rs)		
	2020-21	2019-20	Increase (%)
Average salary of all employees (other than Managerial Personnel) calculated on per month basis	22,092	15,581	41.79
Managerial Personnel:			
Shalin Sudhakarbhair Patel	3,06,079	1,03,256.00	196.43
Shalin Bharatbhair Chokshi	3,06,079	1,03,256.00	196.43
Saurin Gandhi	81,072	69,170	17.21
Raina Singh	7,500	7,500	0.00

F. The key parameters for any variable component of remuneration availed by the directors;

There are no variable components in remuneration package availed by the directors.

G. Affirmation that the Remuneration is as per the Remuneration Policy of the Company:

It is hereby affirmed that the remuneration paid to the Directors, Key Managerial personnel and Senior Management is as per the Remuneration Policy.

H. Statement containing the particulars of employees in accordance with Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

None of the employees of the company employed throughout the financial year 2020-21 and were paid remuneration in excess of the limits prescribed. i.e. Rs. 1.02 Crores per annum.

None of the employees employed for a part of the financial year 2020-21 at a rate which, in aggregate, was in excess of Rs. 8.50 Lacs per month.

None of the employees were employed throughout the financial year or part thereof, was in receipt of remuneration in that year which, in aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole time director or manager and holds by

himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company.

**FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED**

Place: Ahmedabad

Dated: 17th July, 2021

Sd/-

**CHAIRMAN CUM MANAGING DIRECTOR
Shalin Sudharkarbhai Patel
(DIN: 01779902)**

Annexure VIII

Certificate of Non-Disqualification of Directors

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (listing obligations and Requirements) Regulations, 2015)

To,

The Members of

ARVEE LABORATORIES (INDIA) LIMITED

403, Entice, Nr. Jayantilal Park BRTS, Iskcon - Bopal Road,
Ambli, Ahmedabad - 380058

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Arvee Laboratories (India) Limited having CIN: L24231GJ2012PLC068778 and having registered office at 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad - 380058 (hereinafter referred to as 'the company'), produced before us by the Company for the purpose of issuing this certificate in accordance with Regulation 34 (3) read with Schedule V Para-C clause (10) (i) of the SEBI (listing obligations and Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verification (including Directors Identification Number (DIN) status at the Portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers we hereby certify that none of the Directors on the Board of the company as stated below for the Financial Year ending on 31st March, 2021 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of Appointment in Company
1.	Shalin Sudhakarbhair Patel	01779902	01/04/2014
2.	Shalin Bharatbhair Chokshi	00191903	27/01/2012
3.	Vishal Nitin Mehta	07977497	04/12/2017
4.	Chandrakala Ashok Bhatt	07977517	04/12/2017
5.	Neetu Jalan	08719470	12/02/2021
6.	Paragbhair Manubhair Shah	08773974	27/06/2020

Ensuring the eligibility of for the appointment/ continuity of every Director on the


Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For, Jalan Alkesh & Associates,
Company Secretaries**

Sd/-

**Place: Ahmedabad
Date: 17/07/2021**

**Alkesh Jalan [Proprietor]
FCS No.: 10620 COP No. : 4580
UDIN F010620C000477086**



Independent Auditor's Report

To
The Members of
ARVEE LABORATORIES (INDIA) LIMITED
Ahmedabad

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **ARVEE LABORATORIES (INDIA) LIMITED ("the Company")**, which comprises the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the Standalone Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013, as amended in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India, of the state of affairs of the company as at March 31, 2021, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Emphasis of Matter

We draw attention to Note 4.27 of the financial statements, as regards the management's evaluation of COVID-19 impact on the future performance of the company. Our opinion is not modified in respect of this matter.



Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current year. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to be communicated in our report.

Information Other than the Standalone Financial Statements and Auditors' Report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current year and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Sub-section (11) of Section 143 of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the order.



2. As required by Section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) the balance sheet and the statement of profit and loss and cash flows dealt with by this Report are in agreement with the books of account;
- d) in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
- e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act;
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure-B" to this report; Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
- g) In our opinion, the managerial remuneration for the year ended March 31, 2021 has been paid/provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act;
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 as amended, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The Company does not have any pending litigations which would impact its financial position;
 - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

FOR KCJM & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 121324W


CA KABIR MANSURI
PARTNER

MEM.NO : 126585
UDIN : 21126585AAAADQ7911
PLACE : AHMEDABAD
DATE : 17-06-2021




ARVEE LABORATORIES (INDIA) LIMITED

Accounting Year: 2020-21

Annexure – A to the Independent Auditor's Report

Referred to in paragraph 1, under 'Report on Other Legal and Regulatory Requirements' section of our report of even date

1. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
(b) The Company has a regular programme for physical verification in a phased periodic manner, which, in our opinion, is reasonable having regards to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
(c) According to the information and explanations given to us, the records examined by us and based on the examination of the conveyance deeds / registered sale deed provided to us, we report that, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date. In respect of immovable properties of land and building that have been taken on lease and disclosed as fixed assets in the standalone financial statements, the lease agreements are in the name of the Company.
2. (a) As explained to us, Inventories have been physically verified during the year by the management at reasonable interval.
(b) In our opinion and according to the information and explanation given to us, the procedure of physical verification of inventories followed by the management is reasonable and adequate in relation to size of the company and nature of its business.
(c) In our opinion and on the basis of our examination of the records, Company is generally maintaining proper records of its inventories. No material discrepancy was noticed on physical verification of stock by the management as compared to book records.
3. According to the information and explanations given to us and on the basis of our examination of the books of account, The Company has not granted any loans, secured or unsecured, to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013. Consequently, the provisions of clauses (iii) are not applicable.
4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
5. According to the information and explanations given to us, The Company has not accepted any deposits the public within the meaning of section 73 to 76 and the companies (Acceptance of Deposit) Rules, 2014 (As Amended). Therefore, the provisions of the clause (v) of paragraph 3 of the Order are not applicable to the Company.
6. We have broadly reviewed the books of accounts maintained by the company pursuant to the rules made by the central government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the manufacturing activities, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
7. In respect of statutory dues :
(a) According to the records of the Company, undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues have been generally regularly deposited with the appropriate authorities. According to the information and explanation given to us, no undisputed amounts payable in respect of the aforesaid dues were outstanding as at March 31, 2021 for a period of more than six months from the due date of becoming payable.



(b) According to the records of the Company, there are no statutory dues including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues which have not been deposited on March 31, 2021 on account of any dispute.

8. In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowing to a financial institution, bank or government or dues to debenture holders. The company has not borrowed from financial institution, government or debenture holder during the year.
9. In our opinion and according to the information and explanations given to us, moneys raised by way of debt instruments and term loans have been applied by the company for the purposes for which they were raised.
10. In our opinion and according to the information and explanations given to us, no material fraud by the company or on the company by its officers or employees has been noticed or reported during the year.
11. During the period under review, the company has paid/provided managerial remuneration in accordance with the requisite approvals mandated by the provision of section 197 read with schedule V of the Companies Act, 2013.
12. The company is not Nidhi Company and hence reporting under clause (xii) of paragraph 3 of the order is not applicable,
13. In our opinion and according to the information and explanation given to us, the company's transaction with its related party are in compliance with section 177 and 188 of the Companies Act, 2013, where applicable, and details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.
14. During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly paid convertible debentures and hence reporting under clause (xiv) of paragraph 3 of the Order is not applicable to the Company.
15. In our opinion and according to the information and explanations given to us, during the year, the Company has not entered into any non-cash transactions with its Directors or persons connected to its directors and hence reporting under clause (xv) of paragraph 3 of the order is not applicable to the Company.
16. In our opinion and according to information and explanation provided to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934

FOR KCJM & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 121324W


CA KABIR MANSURI
PARTNER

MEM.NO : 126585
UDIN : 21126585AAAADQ7911
PLACE : AHMEDABAD
DATE : 17-06-2021



ARVEE LABORATORIES (INDIA) LIMITED

Accounting Year: 2020-21

ANNEXURE B

TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF ARVEE LABORATORIES (INDIA) LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **ARVEE LABORATORIES (INDIA) LIMITED** as of March 31, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.



Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021 with respect to the transactions of the Company, based on the internal control over financial reporting criteria established by the Bank considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

FOR KCJM & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 121324W


CA KABIR MANSURI
PARTNER

MEM.NO : 126585
UDIN : 21126585AAAADQ7911
PLACE : AHMEDABAD
DATE : 17-06-2021



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Statement of Balance Sheet as at 31st March, 2021


(Amount in Rs.)

Particulars	Note No	As at 31 st March 2021	As at 31 st March 2020
ASSETS			
Non-current assets			
Property, Plant and Equipment	6	13,78,21,783	13,14,63,484
Capital Work-in-Progress	6	96,63,244	1,77,92,053
Other Intangible Assets	7	2,72,519	3,58,019
Financial Assets			
Other Financial Assets	8	24,44,900	21,79,459
Other Non-current Assets	9	47,22,462	60,20,392
Total Non-Current Assets		15,49,24,908	15,78,13,407
Current assets			
Inventories	10	7,43,13,658	6,46,78,655
Financial Assets			
Current Investments	11	2,03,39,590	3,09,41,431
Trade receivables	12	7,88,15,538	6,51,51,560
Cash and cash equivalents	13	6,60,52,896	97,84,890
Other Current Assets	14	1,60,16,860	78,79,383
Total Current Assets		25,55,38,543	17,84,35,919
Total Assets		41,04,63,451	33,62,49,326
EQUITY AND LIABILITIES			
EQUITY			
Equity Share Capital	15	11,02,00,000	5,51,00,000
Other Equity	16	10,41,82,280	13,25,08,752
Total Equity		21,43,82,280	18,76,08,752
LIABILITIES			
Non-Current Liabilities			
Financial Liabilities			
Borrowings	17	1,00,00,000	1,95,72,064
Other Financial Liabilities		-	-
Deferred tax liabilities (Net)	22	31,32,577	42,17,241
Total Non-current liabilities		1,31,32,577	2,37,89,305



Current Liabilities			
Financial Liabilities			
Borrowings	17	7,87,92,000	1,90,95,371
Trade Payables	18	9,54,47,073	10,03,76,833
Other Financial Liabilities		-	-
Provisions	19	74,50,343	32,20,182
Other current liabilities	20	6,65,808	6,79,902
Current Tax Liabilities (Net)	21	5,93,370	14,78,981
Total Current liabilities		18,29,48,594	12,48,51,269
Total Equity and Liabilities		41,04,63,451	33,62,49,326
Significant Accounting Policies	4		
The Notes referred to above form an integral part of these Financial Statements			


As per our separate report of even date attached
For K C J M & Associates
Chartered Accountants


Kabir Mansuri
Partner
Membership No. 126585
FRN :- 121324W




Place : Ahmedabad
Date : 17-06-2021
UDIN : 21126585AAAADQ7911


For and on behalf of the Board of Directors of
Arvee Laboratories (India) Limited


Shalin S Patel
Managing Director
[DIN: 01779902]


Shalin B Chokshi
Whole Time Director
[DIN: 00191903]




Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]


Raina Singh Chauhan
Company Secretary
[M. No. 57624]

Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Statement of Profit and Loss Account for the year ended 31st March, 2021

(Amount in Rs.)

Particulars	Note No	for the year ended 31 st March 2021	for the year ended 31 st March 2020
Revenue from operations	23	47,37,50,132	45,41,87,054
Other Income	24	58,48,206	34,60,682
Total Revenue		47,95,98,338	45,76,47,736
Expenses:			
Cost of Material Consumed	25	29,07,47,358	30,23,95,909
Changes in Inventories of finished Goods, Work-in-Progress and Stock in Trade	26	41,80,055	(1,07,48,902)
Employee benefit expense	27	3,54,27,500	2,79,48,392
Finance costs	28	57,64,953	98,77,740
Depreciation, Amortisation and Impairment expense	29	2,40,66,089	2,28,90,825
Other expenses	30	8,29,97,985	7,43,77,887
Total Expenses		44,31,83,940	42,67,41,851
Profit before exceptional and extraordinary items and tax		3,64,14,398	3,09,05,885
Exceptional & Extraordinary Items			
Profit before tax		3,64,14,398	3,09,05,885
Tax expense:			
Current tax		1,07,25,534	93,57,956
Deferred tax	22	(10,84,664)	(14,41,850)
Net Tax expenses		96,40,870	79,16,106
Profit for the year		2,67,73,528	2,29,89,779
Other Comprehensive Income			
Items that will not be reclassified subsequently to Profit or Loss			
Remeasurement of Defined Benefit Plans		-	-
Changes in Fair Value of FVOCI equity instruments		-	-
Income tax relating to items that will not be reclassified subsequently to Profit or Loss		-	-
Net other comprehensive income not to be reclassified subsequently to Profit and Loss		-	-
Items that will be reclassified subsequently to Profit or Loss			
Debt instruments through other comprehensive income - net change in fair value		-	-
Income tax relating to items that will be reclassified subsequently to Profit or Loss		-	-



Other comprehensive income to be reclassified subsequently to Profit and Loss Total Other Comprehensive income for the year Total Comprehensive income for the year Earning per equity share: (1) Basic (2) Diluted Significant Accounting Policies The Notes referred to above form an integral part of these Financial Statements			
		-	-
		-	-
		2,67,73,528	2,29,89,779
		2.43	2.09
		2.43	2.09
	4		


As per our separate report of even date attached
For K C J M & Associates
Chartered Accountants



Kabir Mansuri
Partner
Membership No. 126585
FRN :- 121324W




Place : Ahmedabad
Date : 17-06-2021
UDIN : 21126585AAAADQ7911

For and on behalf of the Board of Directors of
Arvee Laboratories (India) Limited


Shalin Patel
Managing Director
[DIN: 01779902]


Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]




Shalin Chokshi
Whole Time Director
[DIN: 00191903]


Raina Singh Chauhan
Company Secretary
[M. No. 57624]

Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Statement of Cash Flows for the year ended 31st March, 2021

(Amount in Rs.)

Particulars	for the year ended 31 st March 2021	for the year ended 31 st March 2020
A. Cash Flow from Operating Activities	3,64,14,398	3,09,05,885
Net Profit Before Tax		2,28,90,825
Adjustment for :	2,40,66,089	6,14,600
Depreciation	6,14,600	89,07,319
Amortisation	49,20,642	(13,97,940)
Finance Costs recognised in Statement of Profit and Loss	(28,22,719)	(20,58,757)
Interest Income recognised in Statement of Profit and Loss	(29,48,657)	-
Loss /(Gain) on Sale of Investments	2,05,049	-
Loss /(Gain) on Disposal of Property, Plant & Equipment	6,04,49,402	5,98,61,933
Operating Profit before Working capital Changes		
Adjustment for (Increase) / Decrease in Working Capital :	(96,35,003)	(1,85,83,999)
Inventories	(1,36,63,978)	1,40,02,551
Trade Receivables	(77,19,588)	2,39,25,970
Loans and Advances	(26,83,967)	3,18,26,017
Trade Payables and Provisions	2,67,46,867	11,10,32,472
Cash generated from Operations	(96,40,870)	(79,16,106)
Direct Taxes Paid (Net)	1,71,05,997	10,31,16,366
Net Cash from Operating Activities		
B. Cash Flow from Investing Activities :		
Purchase of Property, Plant and Equipments, other intangible Assets & Capital Work-in-progress	(2,29,06,128)	(2,28,53,304)
Proceeds from Property, Plant and Equipments, other intangible Assets & Capital Work-in-progress	4,91,000	-
Purchase/Sale of Investments	1,06,01,841	(1,14,46,555)
Profit on sale of Investment	29,48,657	20,58,757
Interest received	28,22,719	13,97,940
Net Cash used in Investing Activities	(60,41,912)	(3,08,43,162)
C. Cash Flow from Financing Activities :		
Share Capital Issued	-	-
Security Premium Received	-	(9,00,60,613)
Preliminary Expenses Incurred	5,01,24,565	(89,07,319)
Borrowings	(49,20,642)	(9,89,67,932)
Finance Cost Paid	4,52,03,923	(2,66,94,727)
Net Cash Generated from/(used in) Financing Activities	5,62,68,008	3,64,79,617
Net increase in Cash and Cash Equivalents (A+B+C)	97,84,890	97,84,890
Cash and Cash Equivalents as at 1st April (Opening Balance)	6,60,52,896	
Cash and Cash Equivalents as at 31st March (Closing Balance)		

Notes :

- The above statement of Cash Flows has been prepared under the "Indirect Method" as set out in India Accounting Standard (Ind AS- 7) - Statement of Cash Flow.

As per our separate report of even date attached
For K C J M & Associates
Chartered Accountants

Kabir Mansuri
Partner

Membership No. 126585
FRN :- 121324W

Place : Ahmedabad
Date : 17-06-2021

UDIN : 21126585AAAADQ7911



For and on behalf of the Board of Directors of
Arvee Laboratories (India) Limited

Shalin Patel
Managing Director
[DIN: 01779902]

Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]

Shalin Chokshi
Whole Time Director
[DIN: 00191903]

Raina Singh Chauhan
Company Secretary
[M. No. 57624]



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Statement of Changes in Equity for the year ended 31st March, 2021

a. Equity Share Capital

	(Amount in Rs.)
Balance as at 1 st April, 2019	5,51,00,000
Changes in Equity Share Capital	-
Balance as at 31 st March, 2020	5,51,00,000
Changes in Equity Share Capital - Issue of Bonus Equity Shares	5,51,00,000
Balance as at 31 st March, 2021	11,02,00,000

b. Other Equity

	(Amount in Rs.)
	Total
Balance as at 1 st April, 2019	10,95,18,973
Profit for the Year	2,29,89,779
Other Comprehensive Income for the Year, net of Income Tax	-
Balance as at 31 st March, 2020	13,25,08,752
Profit for the Year	2,67,73,528
Other Comprehensive Income for the Year, net of Income Tax	-
Utilized on Issue of Bonus Shares	(5,51,00,000)
Balance as at 31 st March, 2021	10,41,82,280

As per our separate report of even date attached

For K C J M & Associates

Chartered Accountants

**For and on behalf of the Board of Directors
Arvee Laboratories (India) Limited**

Kabir Mansuri
Partner

Membership No. 126585

FRN :- 121324W

Shalin Patel
Managing Director
[DIN: 01779902]

Shalin Chokshi
Whole Time Director
[DIN: 00191903]

Place : Ahmedabad

Date : 17-06-2021

UDIN : 21126585AAAADQ7911

Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]

Raina Singh Chauhan
Company Secretary
[M. No. 57624]

Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

1. CORPORATE INFORMATION:

Arvee Laboratories (India) Ltd. ("the company") is a listed entity on incorporated in India. The Shares of the company are listed on the NSE Main Board.

The addresses of its registered office is 403, ENTICE Building, Opposite Jayantilal Park BRTS Bus Stop, Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

The plant of the company is situated at Survey No. 316, Bhavnagar Sihor Road, Post: Vartej, Kardej, Dist. Bhavnagar, PIN-364060, Gujarat, India. The company is engaged in manufacturing of specialized chemicals.

2. BASIS OF PREPARATION OF FINANCIAL STATEMENTS::

These financial statements are in accordance with Indian Accounting Standards (IND AS) under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values, the provision of the Companies Act, 2013 ("the Act") (to the extent notified) and guidelines issued by the Securities & Exchange Board of India (SEBI). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 and relevant rules issued thereafter.

The Company has adopted all the Ind AS standards and the adoption was carried out in accordance with Ind AS 101, First-Time Adoption of Indian Accounting Standards. The transition was carried out from Indian Accounting Principles generally accepted in India as prescribed under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (IGAAP), which was the previous GAAP. Reconciliation and descriptions of the effect of the transition have been summarized in Note 5. Accounting policies have been consistently applied except where newly issued accounting standards are initially adopted or a revision to an existing standard requires a change in the Accounting policy hitherto in used.

As the quarter and year figures are taken from the source and rounded to the nearest digit, the figures reported for the previous quarters might not always adopt to the year-end figures reported in these statements.

The Company's presentation and functional currency is Indian Rupees (₹) and all values are rounded to the nearest digits.

3. Use of Estimates:

The preparation of the Company's Ind AS financial statements requires management to make informed judgements, reasonable assumptions and estimates that affect the amounts reported in the financial statements and notes thereto. Uncertainty about these could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in the future periods. These assumptions and estimates are reviewed periodically based on the most recently available information.

Revisions to accounting estimates are recognized prospectively in the Statement of Profit & Loss in the period in which the estimates are revised and in any future periods affected.

In the assessment of the Company, the most significant effects of use of judgments and/or estimates on the amounts recognized in the financial statements relate to the following areas:

- Useful lives of property, plant & equipment;
- Valuation of inventories;
- Measurement of recoverable amounts of assets / cash-generating units;
- Assets and obligations relating to employee benefits;
- Evaluation of recoverability of deferred tax assets; and
- Provisions and Contingencies.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

4. SIGNIFICANT ACCOUNTING POLICIES :

4.1 Current & Non-current Classification:

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle (twelve months) and other criteria set out in Schedule III to the Act.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. Based on the nature of business and its activities, the Company has ascertained its operating cycle as twelve months for the purpose of Current & Non-Current classification of assets and liabilities.

4.2 Property, Plant and Equipment:

4.2.1 Property, Plant and Equipment acquired separately

Freehold land is stated at cost and not depreciated. Buildings, plant and machinery, vehicles, furniture and office equipments are stated at cost less accumulated depreciation and accumulated impairment losses. An item of Property, Plant and Equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of Property, Plant and Equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in Statement of Profit and Loss.

4.2.2 Capital Work-in-Progress

Properties in the course of construction for production, supply or administrative purposes are carried at cost, less any recognized impairment loss. Cost includes professional fees and, for qualifying assets, borrowing costs capitalized in accordance with the Company's accounting policy. Such properties are classified and capitalized to the appropriate categories of Property, Plant and Equipment when completed and ready for intended use. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

4.2.3 Depreciation

Depreciation is recognized so as to write off the cost of assets (other than Freehold Land and Capital Work-in-Progress) less their residual values over their useful lives, using the straight-line method as per the useful life prescribed in Schedule II to the Companies Act, 2013. The life has been decided by the management considering the type and nature of the assets as defined in the Schedule II of the Companies Act, 2013.

4.3 Intangible Assets:

4.3.1 Intangible Assets acquired separately

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

Amortization policies applied to the Company's Intangible Assets to the extent of depreciable amount is as follows:

Particular	Depreciation
Computer Software	over a period of 5 years

4.4 Capital Work in Progress and Capital advances:

Cost of assets not ready for intended use, as on the balance sheet date, is shown as capital work in progress. Advances given towards acquisition of Property, Plant and Equipments outstanding at each balance sheet date are disclosed as Other Non-current Assets.

4.5 Cash Flow Statement :

Cash flows are reported using the indirect method, whereby profit/(loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals or accruals of past or future cash receipts or payments. The cash flows are from operating, investing and financing activities of the Company are segregated based on the available information.

4.6 Transaction in Foreign Currency :

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date.

Exchange differences arising on settlement or translation of monetary items are recognized in Statement of Profit and Loss except to the extent of exchange differences which are regarded as an adjustment to interest costs on foreign currency borrowings that are directly attributable to the acquisition or construction of qualifying assets, are capitalized as cost of assets.

4.7 Financial Instruments :

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

4.8 Loans and Borrowings :

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the Effective Interest Rate (EIR) method. Gains and losses are recognised in Statement of profit or loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of Profit and Loss. Borrowing costs attributable to acquisition or construction of a qualifying asset are capitalized as part of cost of that asset. Other borrowing costs are recognized as expense in the period in which these are incurred.

4.9 Investments :

Investments in mutual funds are classified as Current Investments. Current Investments are valued at lower of cost or fair value.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

4.10 Inventory :

Items of inventories are measured at lower of cost and net realizable value after providing for obsolescence, if any, except in case of by-products which are valued at net realizable value. Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads net of recoverable taxes incurred in bringing them to their respective present location and condition.

Cost of raw materials, chemicals, stores and spares, packing materials, trading and other products are determined on weighted average basis.

4.11 Trade Receivables:

Trade receivables are amounts due from customers for sale of goods in the ordinary course of business. Trade receivables are initially recognized at its transaction price which is considered to be its fair value and are classified as current assets as it is expected to be received within the normal operating cycle of the business.

4.12 Trade Payables:

Trade payables are amounts due to vendors for purchase of goods in the ordinary course of business and are classified as current liabilities to the extent it is expected to be paid within the normal operating cycle of the business.

4.13 Other Financial Assets and Liabilities

Other non-derivative financial instruments are initially recognized at fair value and subsequently measured at amortized costs using the effective interest method.

4.14 De-recognition of financial assets and liabilities

The Company derecognizes a financial asset when the contractual right to the cash flows from the asset expires or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction which substantially all the risk and rewards of ownership of the financial asset are transferred.

The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled or expired; the difference between the carrying amount of derecognized financial liability and the consideration paid is recognized as profit or loss.



4.15 Leases – Company as a lessee

Finance lease

Leases where the Company assumes substantially all the risks and rewards of ownership are classified as finance lease. Such leases are capitalized at the inception of the lease at lower of the fair value or the present value of the minimum lease payments and a liability is recognized for an equivalent amount. Each lease rental paid is allocated between the liability and the interest cost so as to obtain a constant periodic rate of interest on the outstanding liability for each year.

Operating lease

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the lessor, are recognized as operating lease. Operating lease payments are recognized as an expense on a straight line basis over the lease term unless the payments are structured to increase in line with the expected general inflation so as to compensate for the lessor's expected inflationary cost increases.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

4.16 Impairment of Assets

Financial assets

At each balance sheet date, the Company assesses whether a financial asset is to be impaired. Ind AS 109 requires expected credit losses to be measured through loss allowance. The Company measures the loss allowance for financial assets at an amount equal to lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for financial assets at an amount equal to 12-month expected credit losses. The Company uses both forward-looking and historical information to determine whether a significant increase in credit risk has occurred.

Non-financial assets

Tangible assets

Property, plant and equipment with finite life are evaluated for recoverability whenever there is any indication that their carrying amounts may not be recoverable. If any such indication exists, the recoverable amount (i.e. higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the cash generating unit (CGU) to which the asset belongs. If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognized in the statement of profit and loss to such extent. When an impairment loss subsequently reverses, the carrying amount of the asset (or a CGU) is increased to the revised estimate of its recoverable amount, such that the increase in the carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or CGU) in prior years. A reversal of an impairment loss is recognised immediately in statement of profit and loss.

4.17 Borrowing Cost:

All borrowing costs are recognized as expenses in the period in which they are incurred, except to the extent where borrowing costs that are directly attributable to the acquisition, construction or production of an asset till ready for intended use is capitalized as a part of the cost of that asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs (except as stated in notes) is charged to revenue.

4.18 Deferred Revenue Expenditure

Expenditure relating to Preliminary expenses, capital issue and deferred revenue expense is amortized on straight line basis over a period of 5 years.

4.19 Revenue Recognition:

Revenue is measured at the fair value of the consideration received or receivable. Revenue from sale of goods includes excise duty and are net of discounts, applicable taxes, rebates and estimated returns. The revenue is recognized when the significant risks and rewards of ownership of goods are transferred to the buyer, recoverability of consideration is probable, the amount of revenue and cost incurred or to be incurred in respect of the transaction can be measured reliably and there is no continuing managerial involvement over the goods sold.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

MEIS receivable on Export of Goods is recognized on the basis of claim disbursement by the relevant authority.

4.20 Accounting for Taxes on Income:

Income tax expenses are recognized in statement of profit and loss, except when they relate to items recognized in other comprehensive income or directly in equity, in which case, income tax expenses are also recognized in other comprehensive income or directly in equity respectively. Current tax is the tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of reporting period by the governing taxation laws, and any adjustment to tax payable in respect of previous periods. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred taxes arising from deductible and taxable temporary differences between the tax base of assets and liabilities and their carrying amount in the financial statements are recognized using substantively enacted tax rates and laws expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled. The deferred tax arising from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction are not recognized. Deferred tax asset are recognized only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax assets to be utilized. Deferred tax assets and liabilities are offset when the Company has a legally enforceable right to do the same.


4.21 Provisions & Contingencies :

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

4.22 Employee Benefits:

(a) Short term employee benefits are recognized as expenses at the undiscounted amount in the Statement of Profit and Loss of the year for which the related service is rendered.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

b) Defined Contribution Plan: Monthly contribution to the provident fund which is under defined contribution schemes are charged to Statement of Profit & Loss and deposited with the provident fund authorities on monthly basis.

c) Defined Benefit Plans: Gratuities to employees are provided on the basis of actuarial valuation.

d) Termination benefits are charged to the Statement of Profit and Loss in the year of accrual when the Company is committed without any possibility of withdrawal of an offer made to either terminate employment before the normal retirement date or as a result of an offer made to encourage voluntary retirement.

4.23 Segment Reporting:

The company has only one geographical segment and one business segment. Therefore, in the context of Operating Segment under the Indian accounting standard 108 "Segment Information" there is no separate reportable segment.

4.24 Finance Cost :

Finance Cost includes interest, bank charges incurred in connection with the arrangements of borrowing. Finance costs that are directly attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets.

4.25 Cash and Cash Equivalent:

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, as they are considered an integral part of the Company's cash management.

4.26 Earnings per Share:

Basic earnings per share is computed and disclosed using the weighted average number of common shares outstanding during the year. Dilutive earning per share is computed and disclosed using the weighted average number of common and dilutive common equivalent shares outstanding during the year, except when the results would be anti-dilutive.

4.27 Global Health Pandemic on COVID-19:

The Company has considered the possible effects that may result from COVID-19 on the carrying amounts of financial assets, inventory, receivables, loans and advances, property plant and equipment, intangibles etc as well as liabilities accrued. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company has used internal and external information. Having reviewed the underlying data and based on current estimates, the Company does not expect any material impact on the carrying amount of these assets and liabilities. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of these financial statements and the Company will continue to closely monitor any material changes to future economic conditions. The Company has also evaluated the impact of the same on the aforementioned risks i.e. credit risk, liquidity risk, market risk, currency risk and interest risk and does not foresee any material impact on account of the same.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

5. Explanation to transition to Ind AS

As stated in Note 2, these are the Company's first financial statements prepared in accordance with Ind AS. For the year ended 31 March 2020, the Company had prepared its financial statements in accordance with Companies (Accounting Standards) Rules, 2006, notified under Section 133 of the Act and other relevant provisions of the Act ('previous GAAP').

The accounting policies set out in Note 4 have been applied in preparing these financial statements for the year ended 31 March 2021 including the comparative information for the year ended 31 March 2020 and the opening Ind AS balance sheet on the date of transition i.e. 1 April 2019.

In preparing its Ind AS balance sheet as at 1 April 2019 and in presenting the comparative information for the year ended 31 March 2020, the Company has adjusted amounts reported previously in financial statements prepared in accordance with previous GAAP. This note explains the principal adjustments made by the Company in restating its financial statements prepared in accordance with previous GAAP, and how the transition from previous GAAP to Ind AS has affected the Company financial position, financial performance and cash flows.

Optional exemptions availed and mandatory exceptions

In preparing these financial statements, the Company has applied the below mentioned optional exemptions and mandatory exceptions.

A. Optional exemptions availed

1. Property Plant and Equipment

As per Ind AS 101 an entity may elect to:

- (i) measure an item of property, plant and equipment at the date of transition at its fair value and use that fair value as its deemed cost at that date
- (ii) use a previous GAAP revaluation of an item of property, plant and equipment at or before the date of transition as deemed cost at the date of the revaluation, provided the revaluation was, at the date of the revaluation, broadly comparable to:
 - fair Value;
 - or cost of depreciated cost under Ind AS adjusted to reflect, for example, changes in general specific price index.
- (iii) use carrying values of property, plant and equipment as on the date of transition to Ind AS (which are measured in accordance with previous GAAP prescribed under Ind AS 101) if there has been no change in its functional currency on the date of transition.

As permitted by Ind AS 101, the Company has elected to continue with the carrying values under previous GAAP for all the items of property, plant and equipment.

B. Mandatory Exceptions

1. Estimates

As per Ind AS 101, an entity's estimates in accordance with Ind AS at the date of transition to Ind AS at the end of the comparative period presented in the entity's first Ind AS financial statements, as the case may be, should be consistent with estimates made for the same date in accordance with the previous GAAP unless there is objective evidence that those estimates were in error. However, the estimates should be adjusted to reflect any differences in accounting policies.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

As per Ind AS 101, where application of Ind AS requires an entity to make certain estimates that were not required under previous GAAP, those estimates should be made to reflect conditions that existed at the date of transition (for preparing opening Ind AS balance sheet) or at the end of the comparative period (for presenting comparative information as per Ind AS).

The Company's estimates under Ind AS are consistent with the above requirement. Key estimates considered in preparation of the financial statements that were not required under the previous GAAP are listed below:

- Impairment of financial assets based on the expected credit loss model.
- Determination of the discounted value for financial instruments carried at amortised cost.

2. Derecognition of financial assets and liabilities

As per Ind AS 101, an entity should apply the derecognition requirements in Ind AS 109, Financial Instruments, prospectively for transactions occurring on or after the date of transition to Ind AS. However, an entity may apply the derecognition requirements retrospectively from a date chosen by it if the information needed to apply Ind AS 109 to financial assets and financial liabilities derecognised as a result of past transactions was obtained at the time of initially accounting for those transactions. The Company has elected to apply the derecognition principles of Ind AS 109 prospectively for transactions occurring on or after the date of transition to Ind AS.

3. Classification and measurement of financial assets

Ind AS 101 requires an entity to assess classification of financial assets on the basis of facts and circumstances existing as on the date of transition. Further, the standard permits measurement of financial assets accounted at amortised cost based on facts and circumstances existing at the date of transition if retrospective application is impracticable.

Accordingly, the Company has determined the classification of financial assets based on facts and circumstances that exist on the date of transition. Measurement of the financial assets accounted at amortised cost has been done retrospectively except where the same is impracticable.

Reconciliation of Equity as previously reported under GAAP to Ind AS

Particulars	Note	Opening Balance Sheet as at April 1, 2019			Balance Sheet as at March 31, 2020		
		GAAP	Effects of Transition to Ind AS	Ind AS	GAAP	Effects of Transition to Ind AS	Ind AS
Equity							
Equity Share Capital		55100000	-	55100000	55100000	-	55100000
Securities Premium		74460000	-	74460000	74460000	-	74460000
Retained Earnings	A	35058973		35058973	57328731	720021	58048752
Total Equity		164618973		164618973	187608752	-	187608752



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Reconciliation Statement of Total Comprehensive Income as previously reported under GAAP to Ind AS

Particulars	Note	(Amount in Rs.)		
		Balance Sheet as at March 31, 2020		
		GAAP	Effects of Transition to Ind AS	Ind AS
Revenue from Operations		454187054	-	454187054
Other Income		3460682	-	3460682
Total Income		457647736	-	457647736
Expenses		426741851	-	426741851
Profit Before Tax		30905885	-	30905885
Less: Tax Expense	A	8636127	(720021)	7916106
Profit After Tax		22269758	720021	22989779
Other Comprehensive Income		-	-	-
Total Comprehensive Income		22269758	720021	22989779

Notes to Reconciliation between previous GAAP and Ind AS:

A. Provision of Current Tax

As per Ind AS 8, *Accounting Policies, Change in Accounting Estimate and Errors*, in the event of change in estimate, such change shall be applied retrospectively except to the extent that it is impracticable to determine the prior period effect or cumulative effect. The difference between provision of Current Tax and Actual Tax has been provided retrospectively in the comparative statements.

Cash Flow Statement

There were no significant reconciliation items between cash flows prepared under GAAP and those prepared under Ind AS.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

i. Property, Plant and Equipments and Capital Work-in-Progress

Reconciliation of Carrying Amount

Carrying Amount	As at 31 st March, 2021	As at 31 st March, 2020
Land	20,00,000	20,00,000
Building	4,82,54,342	3,81,77,479
Plant & Machinery	7,49,72,362	8,09,45,313
Laboratory Equipment	2,47,601	3,10,437
Electric Installation	40,01,766	36,68,385
Furniture & Fixtures	47,69,629	29,38,541
Office Equipments	16,81,570	15,87,468
Computer and Printers	4,43,580	2,69,966
Vehicles	14,50,933	15,65,895
Capital Work-in-Progress	13,78,21,783	13,14,63,484
Total	14,74,85,027	14,92,55,537



Particulars	Land	Building	Plant & Machinery	Laboratory Equipment	Electric Installation	Furniture & Fixtures	Office Equipments	Computer and Printers	Vehicles	Total
Gross Carrying Amount										
Balance as at 1 April, 2019	20,00,000	4,11,80,863	16,02,69,989	6,74,000	59,51,390	7,42,640	15,96,723	7,43,251	27,84,890	21,59,43,746
Additions	-	48,96,154	1,82,30,964	86,144	13,39,161	24,58,739	9,60,365	2,49,772	-	2,82,21,299
Disposals	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March, 2020	20,00,000	4,60,77,017	17,85,00,953	7,60,144	72,90,551	32,01,379	25,57,088	9,93,023	27,84,890	24,41,65,045
Additions	-	1,15,54,278	1,46,45,060	73,784	8,75,385	22,50,123	5,50,903	2,64,198	8,21,206	3,10,34,937
Disposals	-	-	-	-	-	-	-	-	12,62,432	12,62,432
Balance as at 31 March, 2021	20,00,000	5,76,31,295	19,31,46,013	8,33,928	81,65,936	54,51,502	31,07,991	12,57,221	23,43,664	27,39,37,550
Accumulated Depreciation and Impairment										
Balance as at 1 April, 2019	-	65,89,521	7,76,66,583	3,26,388	30,90,281	86,899	6,17,977	6,28,854	8,89,733	8,98,96,236
Depreciation Expense	-	13,10,017	1,98,89,057	1,23,319	5,31,885	1,75,939	3,51,643	94,203	3,29,262	2,28,05,325
Eliminated on Disposal of Asset	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March, 2020	-	78,99,538	9,75,55,640	4,49,707	36,22,166	2,62,838	9,69,620	7,23,057	12,18,995	11,27,01,561
Depreciation Expense	-	14,77,415	2,06,18,011	1,36,620	5,42,004	4,19,035	4,56,801	90,584	2,40,119	2,39,80,589
Eliminated on Disposal of Asset	-	-	-	-	-	-	-	-	5,66,383	5,66,383
Balance as at 31 March, 2021	-	93,76,953	11,81,73,651	5,86,327	41,64,170	6,81,873	14,26,421	8,13,641	8,92,731	13,61,15,767
Net Carrying Amount										
Balance as at 1 April, 2019	20,00,000	3,45,91,342	8,26,03,406	3,47,612	28,61,109	6,55,741	9,78,746	1,14,397	18,95,157	12,60,47,510
Additions	-	48,96,154	1,82,30,964	86,144	13,39,161	24,58,739	9,60,365	2,49,772	-	2,82,21,299
Disposals	-	-	-	-	-	-	-	-	-	-
Depreciation Expense	-	13,10,017	1,98,89,057	1,23,319	5,31,885	1,75,939	3,51,643	94,203	3,29,262	2,28,05,325
Eliminated on Disposal of Asset	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March, 2020	20,00,000	3,81,77,479	8,09,45,313	3,10,437	36,68,385	29,38,541	15,87,468	2,69,966	15,65,895	13,14,63,484
Additions	-	1,15,54,278	1,46,45,060	73,784	8,75,385	22,50,123	5,50,903	2,64,198	8,21,206	3,10,34,937
Disposals	-	-	-	-	-	-	-	-	12,62,432	12,62,432
Depreciation Expense	-	14,77,415	2,06,18,011	1,36,620	5,42,004	4,19,035	4,56,801	90,584	2,40,119	2,39,80,589
Eliminated on Disposal of Asset	-	-	-	-	-	-	-	-	5,66,383	5,66,383
Balance as at 31 March, 2021	20,00,000	4,82,54,342	7,49,72,362	2,47,601	40,01,766	47,69,629	16,81,570	4,43,580	14,50,933	13,78,21,783

Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Goodwill and Other Intangible Assets

Reconciliation of Carrying Amount

Carrying Amount	As at 31 st March, 2021	As at 31 st March, 2020
Computer Software	-	-

Particulars	Computer Software	Total
Gross Carrying Amount		
Balance as at 1 April, 2019	4,50,000	4,50,000
Additions	-	-
Disposals	-	-
Balance as at 31 March, 2020	4,50,000	4,50,000
Additions	-	-
Disposals	-	-
Balance as at 31 March, 2021	4,50,000	4,50,000

Accumulated Depreciation and Impairment

Balance as at 1 April, 2019	6,481	6,481
Depreciation Expense	85,500	85,500
Eliminated on Disposal of Asset	-	-
Balance as at 31 March, 2020	91,981	91,981
Depreciation Expense	85,500	85,500
Eliminated on Disposal of Asset	-	-
Balance as at 31 March, 2021	1,77,481	1,77,481

Net Carrying Amount

Balance as at 1 April, 2019	4,43,519	4,43,519
Additions	-	-
Disposals	-	-
Depreciation Expense	85,500	85,500
Eliminated on Disposal of Asset	-	-
Balance as at 31 March, 2020	3,58,019	3,58,019
Additions	-	-
Disposals	-	-
Depreciation Expense	85,500	85,500
Eliminated on Disposal of Asset	-	-
Balance as at 31 March, 2021	2,72,519	2,72,519



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

8. Other Financial Assets - Non Current

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Security Deposits				
Unsecured, considered good		24,44,900		21,79,459
Doubtful				
Total		24,44,900		21,79,459

9. Other Non Current Assets

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Misc. Expenditure to the extent not W/off		6,52,100		12,66,700
Balance with Government Authorities		24,48,692		24,48,692
Advance to Suppliers for Capital Goods		16,21,670		23,05,000
Total		47,22,462		60,20,392

10. Inventories (valued at lower of cost or net realizable value)

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Raw Material		4,71,79,367		3,35,38,136
Finished Goods		2,67,44,773		3,09,24,828
Work in progress		-		-
Stores and Spares		2,43,218		94,026
Packing Material		1,46,300		1,21,665
Total		7,43,13,658		6,46,78,655

11. Current Investments

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Investments in Mutual Funds				
- SBI Liquid Fund Regular Growth		2,03,39,590		80,81,731
- Investment in 8.85% HDFC Bank Perpetual		-		2,28,59,700
Total		2,03,39,590		3,09,41,431



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

12. Trade Receivables

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Debt outstanding for a period exceeding six months				
Unsecure considered good		9,48,580		3,62,404
Doubtful		-		-
Debt outstanding for a period not exceeding six months				
Unsecure considered good		7,78,66,958		6,47,89,156
Doubtful		-		-
(a) Debt due by Directors		-		-
(b) Debt due by Relatives of Directors		-		-
(c) Debt due by Firm or Companies in which Directors are interested		-		-
Total		7,88,15,538		6,51,51,560

13. Cash and cash Equivalents

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Cash on hand		12,49,588		11,96,634
Balances with banks				
- In Current Accounts		2,98,27,667		24,63,538
- In EEFC Accounts		1,22,85,969		11,55,666
- In Fixed Deposits		2,26,89,672		49,69,052
Total		6,60,52,896		97,84,890

14. Other Current Assets

Particulars	As at 31 March, 2021		As at 31 March, 2020	
Balance with Government Authorities				
- Unsecured, Considered Good		98,46,904		51,88,187
Advance to Staff				
- Unsecured, Considered Good		5,78,677		4,25,063
Advance to Suppliers				
- Unsecured, Considered Good		2,78,014		1,42,196
Other Receivables		53,13,265		21,23,937
Total		1,60,16,860		78,79,383



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

15. Share Capital

Particulars	As at 31 March, 2021	As at 31 March, 2020
Authorised		
1,12,50,000 (Previous year 60,00,000) Equity Shares of Rs. 10/- each	11,25,00,000	6,00,00,000
Issued, Subscribed and fully paid up capital		
1,10,20,000 (Previous year 55,10,000) Equity Shares of Rs. 10/- each	11,02,00,000	5,51,00,000
Total	11,02,00,000	5,51,00,000

a. The reconciliation of the number of Equity Shares and amount outstanding at the beginning and at the end of the reporting period is set out below:

Particulars	As at 31 March, 2021		As at 31 March, 2020	
	Number of Shares	Amount in Rs.	Number of Shares	Amount in Rs.
Shares outstanding at the beginning of the year	55,10,000	5,51,00,000	55,10,000	5,51,00,000
Shares Issued during the year	-	-	-	-
Bonus Shares Issued during the year	55,10,000	5,51,00,000	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	1,10,20,000	11,02,00,000	55,10,000	5,51,00,000

*during the Year of 2020-21, bonus shares were issued in the ratio of 1:1.

b. Terms / Rights attached to Equity Shares

The Company has only one class of equity shares having a par value of Rs.10/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing annual general meeting.

During the year ended 31st March 2021, No dividend is declared by Board of Directors. (Previous year - Nil)

c. Shares held by Holding / Ultimate holding company and/or their subsidiaries/associates: Not

d. Shares reserved for issue under options: NIL

e. Aggregate number of bonus shares issued, shares issued for consideration other than cash and shares brought back during the period of five years immediately preceding the reporting date:

	As at 31 March, 2021	As at 31 March, 2020
	Number of Shares	Number of Shares
Equity shares with voting rights		
- Bonus Shares Issued during the year	55,10,000	-

*Bonus shares were issued in the ratio of 1:1 on 14th October 2020.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

f. Securities convertible into equity / preference shares issued along with the earliest date of conversion:

g. Forfeited Shares : NIL

h. Details of Shareholders holding more than 5% shares in the company:

Name of Shareholder	As at 31 March, 2021		As at 31 March, 2020	
	No. of Shares held	% of shares held	No. of Shares held	% of shares held
Bhartbhai R. Chokshi	13,70,000	12.43%	6,85,000	12.43%
Saumilbhai B. Chokshi	13,38,000	12.14%	6,69,000	12.14%
Shalinbhai B. Chokshi	13,38,000	12.14%	6,69,000	12.14%
Shalinbhai S. Patel	33,80,000	30.67%	16,90,000	30.67%
Sudhakarbhai C. Patel	6,62,000	6.01%	3,31,000	6.01%
Total	80,88,000	73.39%	40,44,000	73.39%

16. Other Equity

Particulars	As at 31 March, 2021	As at 31 March, 2020
Securities Premium Account		
Opening balance	7,44,60,000	7,44,60,000
Add: on Fresh Issues of Equity Shares	-	-
Less: on Issues of Bonus Equity Shares	5,51,00,000	-
Closing Balance	1,93,60,000	7,44,60,000
Retained Earnings		
Opening balance	5,80,48,752	3,50,58,973
(+) Net Profit for the current year	2,67,73,528	2,29,89,779
Closing Balance	8,48,22,280	5,80,48,752
Total	10,41,82,280	13,25,08,752

17. Borrowings

Particulars	As at 31 March, 2021	As at 31 March, 2020
Secured		
Term Loan From bank	-	2,53,05,916
Cash Credit Facility	-	21,11,519
Export Packing Credit Facility	7,87,92,000	-
Unsecured		
Loans from Directors	-	-
Loans from Related Parties	1,00,00,000	1,12,50,000
[Unsecured Loans are taken in pursuance of stipulation of basic requirement]		
Total	8,87,92,000	3,86,67,435
Non Current	1,00,00,000	1,95,72,064
Current	7,87,92,000	1,90,95,371



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

details of security of the borrowings are set out below :

Description of Security offered to Standard Chartered Bank by way of Exclusive first charge of the following property/assets:

1. Hypothecation of Plant and Machinery of the company.
2. Registered Mortgage over the company's 1. R.S. No. 316 paiki Plot No 1 area admeasuring about 7183 sq mtr with construction thereon mouje kardej Ta. & Dist Bhavnagar, 2. residential flat No 403, Kailash Apartment, Nr. Gogha Circle, Bhavnagar & residential flat No 103, Pruthvi Plaza, Nr Gogha Circle, Bhavnagar.
3. First charge on entire current assets of the company including Raw Materials, Stock in process, Finished goods, spares & Receivables (not more than 90 days) present and future.
4. Personal Guarantee of Directors

Rate of Interest & Repayment terms of Loans:

1. Term Loans taken from Standard Chartered Bank bear 3MCLR+1.80 rate of interest per annum.
2. Term Loans taken from Standard Chartered Bank are repayable in 60 monthly installments.
3. Cash Credit Loans taken from Standard Chartered Bank bear 1MCLR+1.70 rate of interest per annum.
4. Export Packing Credit taken from Standard Chartered Bank bear LIBOR+200BPS rate of interest per annum.
5. Short Term Loans taken from Standard Chartered Bank are repayable on demand.

Rate of Interest & Repayment terms of Unsecured loans taken from Directors:

1. Unsecured Loans taken from Directors bear 15% rate of interest per annum
2. Unsecured Loans taken from Directors are repayable after 5 years from the date of acceptance.

Rate of Interest & Repayment terms of Unsecured loans taken from Related parties:

1. Unsecured Loans taken from Related Parties bear 15% rate of interest per annum.
2. Unsecured Loans taken from Related Parties are repayable after 5 years from the date of acceptance.

18. Trade Payables

Particulars	As at 31 March, 2021	As at 31 March, 2020
Trade Payables		
- for Capital Goods		
- Micro, Small and Medium Enterprises		
- Others	4,99,170	27,14,405
- for Expenses		
- Micro, Small and Medium Enterprises		7,86,604
- Others	34,15,094	55,77,003
- for Goods		
- Micro, Small and Medium Enterprises		27,21,071
- Others	9,15,32,809	8,85,77,750
Total	9,54,47,073	10,03,76,833

The information regarding Micro, Small and Medium Enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the Auditors.



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Provisions

Particulars	As at 31 March, 2021	As at 31 March, 2020
Provision for employees benefits	47,35,237	23,52,67
Provision for Expenses	27,15,106	8,67,51
Total	74,50,343	32,20,18

20. Other Current Liabilities

Particulars	As at 31 March, 2021	As at 31 March, 2020
Statutory Dues	6,35,808	6,49,902
Advance From Customers	-	-
Unpaid Auditor's Remuneration	30,000	30,000
Total	6,65,808	6,79,902

21. Current Tax Liabilities (Net)

Particulars	As at 31 March, 2021	As at 31 March, 2020
Provision for Taxation (Net of Advance Tax and Tax deducted at sources)	5,93,370	14,78,98
Total	5,93,370	14,78,98

22. Deffered Tax Liabilities (Net)

Particulars	As at 31 March, 2021	As at 31 March, 2020
As at the beginning of the year	42,17,241	56,59,09
Charge/(credit) to Statement of Profit and Loss	(10,84,664)	(14,41,85)
As at the end of the year	31,32,577	42,17,24
Total	31,32,577	42,17,24



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

23. Revenue from operations

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Sales of Products		
(a) Domestic Sales		
(i) By way of Manufacturing	24,82,65,619	22,05,85,559
(ii) By way of Trading	3,42,19,500	1,64,54,077
(b) Export Sales		
(i) By way of Manufacturing	17,91,42,153	21,13,84,032
(ii) By way of Trading	98,10,238	-
Other Operating Income	23,12,622	57,63,386
Total	47,37,50,132	45,41,87,054

24. Other Income

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Interest Income	7,87,219	13,97,940
Interest on Investment in 8.85% HDFC Bank Perpetual	20,35,500	-
Profit on sale of Liquid Funds	29,48,657	20,58,757
Miscellaneous Income	76,831	3,985
Total	58,48,206	34,60,682

25. Cost of Material Consumed

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Inventory at the beginning of the year	3,35,38,136	2,56,06,260
Add : Purchases	30,43,88,589	31,03,27,785
Less : Inventory at the end of the year	(4,71,79,367)	(3,35,38,136)
Total	29,07,47,358	30,23,95,909



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

26. Changes in Inventories of finished Goods, Work-in-Progress and Stock in Trade

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
<u>Inventories at the end of the year</u>		
Closing stock of finished goods	2,67,44,773	3,09,24,828
Closing stock of work in progress	-	-
	2,67,44,773	3,09,24,828
<u>Inventories at the beginning of the year</u>		
Opening stock of finished goods	3,09,24,828	1,99,75,983
Opening stock of work in progress	-	1,99,943
	3,09,24,828	2,01,75,926
Net (Increase) / decrease	41,80,055	(1,07,48,902)

27. Employee Benefits Expense

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Salaries and Wages	3,35,69,022	2,64,90,786
Contribution to Provident Fund and Other Funds	5,17,043	6,81,946
Staff Welfare Expenses	13,41,435	7,75,660
Total	3,54,27,500	2,79,48,392

28. Finance Costs

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Interest Expenses		
- paid for Cash Credit & EPC	14,16,578	14,67,012
- paid for Term Loans	12,65,875	37,97,177
- paid for Unsecured loans	16,46,918	34,65,354
- paid for Others	5,91,271	1,77,776
Bank charges	8,44,311	9,70,421
Total	57,64,953	98,77,740



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

29. Depreciation, Amortisation and Impairment expense

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Depreciation on Property, Plant and Equipment	2,39,80,589	2,28,05,325
Depreciation on Other Intangible Assets	85,500	85,500
Impairment in value of Capital Work-in-Progress	-	-
Total	2,40,66,089	2,28,90,825

30. Other Expenses

Particulars	for the year ended 31st March 2021	for the year ended 31st March 2020
Administrative Expenses		12,141
Annual Fees	-	2,030
Books & Periodicals	-	-
Bad Debts	8,38,276	-
Communication Expenses	2,70,986	3,49,812
Audit Fees	30,000	30,000
Listing Related Expenses	11,50,155	1,01,960
Keyman Insurance Premium	2,00,00,000	2,00,00,000
Insurance Expense	7,84,343	8,17,639
Professional & Consulting Fees	22,52,789	13,52,825
Membership Fees	1,53,255	8,49,694
Office & General Exp.	6,23,202	4,33,104
Petrol & Conveyance Exp	2,46,242	2,65,496
Postage & Courier Exp	72,797	1,62,247
Printing & Stationary Expenses [Bvn]	1,06,717	1,03,730
Rent Rates & Taxes	17,61,748	3,22,929
Vehicle Repairing Exp [Bvn]	87,591	48,912
Sundry Amount Written Off	-	4,31,820
Service Tax	4,02,677	4,006
Security Exps	11,86,638	12,63,448
Preliminary Expenses written off	6,14,600	6,14,600
Loss on Sale of Fixed Assets	2,05,049	-
Loss on Foreign Currency Transactions	86,928	-
Miscellaneous Expnese	3,81,027	16,26,867
	3,12,55,019	2,87,93,260



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Manufacturing Expenses		
Stores & Consumables	81,11,609	1,09,97,728
Power and Fuel	1,71,76,389	1,49,72,142
Job Work Charges	-	15,91,050
Freight & Transport Charges	29,55,416	24,23,440
Other Manufacturing Exps.	52,77,974	21,74,224
	3,35,21,388	3,21,58,584
Selling and Distribution Expenses		
Advertisement Exp	44,196	-
Travelling Expense Foreign	-	4,04,017
Travelling Expense. Local	39,216	6,76,753
Business Promotion Expenses	96,400	1,57,507
ECGC Premium	1,62,000	1,41,750
Export Related Expenses	1,17,93,703	74,19,344
Export Sales Commission	60,86,063	46,26,672
	1,82,21,578	1,34,26,043
Total	8,29,97,985	7,43,77,887



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

31. Figures of previous year are regrouped and rearranged whenever necessary and rounded off to the nearest rupee for better presentation of accounts. The notes referred in the balance sheet and profit and loss statement form an integral part of the accounts. The Debit and Credit balances of debtors, creditors, loans and advances and unsecured loans are subject to confirmation and reconciliation.
32. In the opinion of the Directors, and to the best of their knowledge and belief, the value of realization of current assets and loans and advances in the ordinary course of business would not be less than the amount at which they are stated in the balance sheet. Provision for all known liabilities is adequate and not in excess of amount reasonably necessary.
33. Considering the nature of Company's business and operation, there are no separate reportable segments (business or geographical) in the context of Operating Segment under the Indian accounting standard 108 "Segment Information".

34. Audit Fees

(Amount in Rs.)

Sr. No	Particulars	2020-21	2019-20
1	Audit Fees	30,000/-	30,000/-
2	Taxation Matters	-	-

35. Related Party Disclosure – AS 18

a. Related Parties and their relationship

Name of the related party	Relationship
Mr. Shalin Patel	Key Managerial Personnel
Mr. Shalin Chokshi	Key Managerial Personnel
Mr. Sudhakar Patel	Director's Father
Mrs. Forum S Chokshi	Director's Relative
Mrs. Kavita S Chokshi	Director's Wife
Mrs. Khusboo S Patel	Director's Wife
Mr. Bharatbhai R Chokshi	Director's Father
Mr. Shalin Chokshi HUF	Director's HUF
Mr. Shalin Patel HUF	Director's HUF
Mr. Saumil Chokshi HUF	Director's Brother's HUF
Mr. Sudhakar C Patel HUF	Director's Father's HUF
Mrs. Chandrabalaben S Patel	Director's Mother
B Chokshi Chem Pvt. Ltd.	Associate Concern
Arvee Speciality Chemicals Private Limited	Associate Concern
Optus Laminates Pvt Ltd.	Associate Concern
Applitech Infotech Pvt Ltd.	Associate Concern



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

b. Transactions with Related Parties

Sr. No.	Name of Related Party	Interest paid		Remuneration		Rent paid		Loan Taken		Loan Repaid		Closing Balance	
		2020-21	2019-20	2020-21	2019-20	2020-21	2019-20	2020-21	2019-20	2020-21	2019-20	2020-21	2019-20
Key Managerial Personnel:													
1.	Mr. Shalin Patel	-	-	3672946	1239081	648180	-	-	-	-	-	-	-
2.	Mr. Shalin Chokshi	-	215825	3672946	1239081	-	-	9750000	-	-	9965825	-	-
Relatives of Key managerial Personnel:													
3.	Mr Sudhakar Patel	253233	-	-	-	-	-	7800000	-	-	-	7800000	-
4.	Ms Khushboo Patel	728712	934273	-	-	-	-	-	-	6200000	-	-	6200000
5.	Ms Forum Chokshi	-	491829	-	-	-	-	-	3300000	-	3791829	-	-
6.	Ms Kavita Chokshi	-	28517	-	-	431148	-	-	240788	-	269305	-	-
7.	Mr. Shalin Patel HUF	333974	429464	-	-	-	-	-	-	2850000	-	-	2850000
8.	Mr. Shalin Chokshi HUF	-	296984	-	-	-	-	-	10000000	-	10296984	-	-
9.	Mr Saumil Chokshi HUF	-	736946	-	-	-	-	-	10000000	-	10736946	-	-
10.	Mr Sudhakar Patel HUF	330000	331516	-	-	-	-	-	-	-	-	2200000	2200000

Page 125 of 128



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

Associate Concern:

Nature of Transactions	2020-21	2019-20
Purchase of Goods		
B. Chokshi Chem Pvt Ltd	5857329	5797242
Sale of Goods		
B. Chokshi Chem Pvt Ltd	-	1851090
Payment of Lease Rent		
Arvee Speciality Chemicals Private Limited	394520	-
Closing Balance		
B. Chokshi Chem Pvt Ltd	1033994	-

36. In compliance of Ind AS-33, Earnings per share, issued by the ICAI, the elements considered for calculation of earnings per share (Basic and Diluted) as under:

Particulars	Current year Amount	Previous year Amount
Net profit/(Loss) after tax available for the equity share holders	26,773,528	22,989,779
Weighted average number of equity shares	11,020,000	11,020,000
Nominal/Face value of equity shares (Rupees)	10	10
Basic and Diluted earnings per share	2.43	2.09

37. Taxation :

37.1 Deferred Tax Liabilities:

Particulars of Deferred Tax	2020-21		2019-20	
	Asset	Liability	Asset	Liability
Opening Balance	-	4,384,515	-	5,788,112
WDV as per Companies Act, 2013	-	136,094,302	-	129,821,503
WDV as per Income Tax, 1961	-	121,352,688	-	114,061,206
Diff. in WDV due to timing difference	-	14,741,614	-	15,760,297
Deferred tax liability for the year – Balance Sheet Item	-	3,710,170	-	4,384,515
Net Deferred Tax Exps /(Income) – Profit & Loss Item	-	(674,345)	-	(1,403,597)
Opening Balance	167,273	-	129,021	-
Net Disallowance of Provision for Gratuity	22,94,947	-	601,270	-
Deferred tax Asset – Balance Sheet Item	577,592	-	167,273	-
Net Deferred Tax Exps / (Income) – Profit & Loss Item	(410,319)	-	(38,252)	-
Net Deferred Tax Exps / (Income)	-	(1,084,664)	-	(1,441,850)

Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

recognized in Profit & Loss				
Net Deferred Tax liability (Asset) reflected in Balance Sheet	-	3,132,577	-	4,217,241

37.2 Current Tax :

Particulars of Current Tax	2020-21	2019-20
Profit Before Tax	36,414,398	30,905,885
Add : Expenses to the extent disallowable	26,032,824	23,165,311
Less : Expenses to the extent Allowable	19,831,463	20,433,682
Less: Adjustment of Brought Forward Loss	-	-
Net Taxable Profit	42,615,759	33,637,513
Current Tax at Applicable Rate*	10,725,534	9,357,956
Less : MAT Credit Entitlement	-	-
Net Current Tax recognized in P&L Account	10,725,534	9,357,956

Income tax rate for 2020-21 is 25.168 % whereas for 2019-20 is 27.82%

38. Other Information:

a) CIF value of Imports:

Particulars	2020-21	2019-20
Raw Material	168,735,501	167,391,908

b) Particulars of Expenditure in Foreign Exchange:

Particulars	2020-21	2019-20
Export sales commission	4,744,904	2,552,922
Travelling Expense	-	155,201

c) Particulars of Earnings in Foreign Exchange:

Particulars	2020-21	2019-20
Export of goods on FOB basis	188,952,391	200,621,233
C & F Charges	-	10,194,141

d) Consumption of Material:

Particulars	2020-21		2019-20	
	Amount Rs.	%	Amount Rs.	Amount Rs.
Raw Material				
- Indigenous	107,648,252	39.91%	129,984,983	42.99%
- Imported(CIF basis)	162,100,400	60.09%	172,410,926	57.01%
Total	269,748,652	100.00%	302,395,909	100.00%



Arvee Laboratories (India) Limited

CIN: L24231GJ2012PLC068778

Notes to Financial Statements for the year ended 31st March, 2021

e) Unhedged Foreign Currency Exposure:

Particulars	Currency	2020-21	2019-20
Receivable	USD	444,454.02	75,992.50
Payable	USD	1,841,580.00	0.00
Receivable	EURO	0.00	622,676.50
Payable	EURO	0.00	0.00

39. Contingent liabilities and commitments

Contingent liabilities and commitments (to the extent not provided for)	AS AT 31.3.2021	AS AT 31.3.2020
(i) Contingent Liabilities		
(a) Claims against the company not acknowledged as debt	Nil	32560
(b) Guarantees	Nil	Nil
(c) Other money for which the company is contingently liable	Nil	Nil
(ii) Commitments		
(a) Estimated amount of contracts remaining to be executed on capital account and not provided for	Nil	Nil
(b) Uncalled liability on shares and other investments partly paid	Nil	Nil
(c) Other commitments (specify nature) (LC discounted)	Nil	Nil

40. Other disclosure required under schedule – III of Companies Act, 2013 are either Nil or Not Applicable.

As per our separate report
of even date attached herewith

For K C J M & Associates
Chartered Accountants

Kabir Mansuri
(Partner)
Membership No. : 126585
Firm Registration no :- 121324W



Place : Ahmedabad
Date : 17/06/2021
UDIN : 21126585AAAADQ7911

For Arvee Laboratories (India) Limited

Shalin Patel
Managing Director
DIN: 01779902

Saurin A Gandhi
Chief Financial Officer
PAN: AJUPG7995F

Shalin Chokshi
Whole Time Director
DIN: 00191903

Raina Singh Chauhan
Company Secretary
M. No. 57624

